Original Article
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
N Engl J Med 2005; 352:1293-1304March 31, 2005
- Abstract
Background
Randomized trials have shown that low-dose aspirin decreases the risk of a first myocardial infarction in men, with little effect on the risk of ischemic stroke. There are few similar data in women.
Methods
We randomly assigned 39,876 initially healthy women 45 years of age or older to receive 100 mg of aspirin on alternate days or placebo and then monitored them for 10 years for a first major cardiovascular event (i.e., nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes).
Results
During follow-up, 477 major cardiovascular events were confirmed in the aspirin group, as compared with 522 in the placebo group, for a nonsignificant reduction in risk with aspirin of 9 percent (relative risk, 0.91; 95 percent confidence interval, 0.80 to 1.03; P=0.13). With regard to individual end points, there was a 17 percent reduction in the risk of stroke in the aspirin group, as compared with the placebo group (relative risk, 0.83; 95 percent confidence interval, 0.69 to 0.99; P=0.04), owing to a 24 percent reduction in the risk of ischemic stroke (relative risk, 0.76; 95 percent confidence interval, 0.63 to 0.93; P=0.009) and a nonsignificant increase in the risk of hemorrhagic stroke (relative risk, 1.24; 95 percent confidence interval, 0.82 to 1.87; P=0.31). As compared with placebo, aspirin had no significant effect on the risk of fatal or nonfatal myocardial infarction (relative risk, 1.02; 95 percent confidence interval, 0.84 to 1.25; P=0.83) or death from cardiovascular causes (relative risk, 0.95; 95 percent confidence interval, 0.74 to 1.22; P=0.68). Gastrointestinal bleeding requiring transfusion was more frequent in the aspirin group than in the placebo group (relative risk, 1.40; 95 percent confidence interval, 1.07 to 1.83; P=0.02). Subgroup analyses showed that aspirin significantly reduced the risk of major cardiovascular events, ischemic stroke, and myocardial infarction among women 65 years of age or older.
Conclusions
In this large, primary-prevention trial among women, aspirin lowered the risk of stroke without affecting the risk of myocardial infarction or death from cardiovascular causes, leading to a nonsignificant finding with respect to the primary end point.
Media in This Article
Figure 1
Cumulative Incidence Rates of the Primary End Point of Major Cardiovascular Events.Figure 2
Cumulative Incidence Rates of Stroke, Myocardial Infarction, Ischemic Stroke, and Hemorrhagic Stroke.Article Activity
- Article
Although aspirin is effective in the treatment of acute myocardial infarction and in the secondary prevention of cardiovascular disease among both men and women,1 its use in primary prevention remains controversial. To date, five randomized trials involving 55,580 participants have evaluated aspirin in the primary prevention of cardiovascular disease.2-6 In aggregate, these trials indicate that, as compared with placebo, aspirin therapy was associated with a significant, 32 percent reduction in the risk of myocardial infarction, but the data on the risk of stroke and death from cardiovascular disease remain inconclusive.7 Moreover, three of these trials evaluated men exclusively, and fewer than 180 of the 2402 vascular events occurred in women. Thus, at this time, the current recommendations for the use of aspirin in primary prevention in women are based on limited direct data from women.8-10
Direct evidence regarding the effects of aspirin in women is necessary because cardiovascular disease is the leading cause of death among both women and men. Direct evidence is also relevant because of the potential for sex-based differences in salicylate metabolism11 and continuing uncertainty regarding the cardiovascular effects of hormone-replacement therapy.12 Moreover, in addition to a paucity of data on women, the prophylactic use of aspirin in both sexes has prompted concern owing to the potentially increased risk of hemorrhagic stroke.13 This issue is particularly complex, since the relative proportion of stroke to myocardial infarction differs between women and men.
We addressed these questions in the Women's Health Study, a large randomized, double-blind, placebo-controlled trial of low-dose aspirin in the primary prevention of cardiovascular disease among 39,876 apparently healthy women followed for a mean of 10 years for the major cardiovascular events of myocardial infarction, stroke, and death from cardiovascular causes.
Methods
Study Design
The Women's Health Study is a two-by-two factorial trial evaluating the balance of risks and benefits of low-dose aspirin (100 mg every other day; Bayer HealthCare) and vitamin E (600 IU every other day; Natural Source Vitamin E Association), in the primary prevention of cardiovascular disease and cancer. The trial was designed to evaluate the lowest dose of aspirin that would have a cardioprotective effect, while minimizing gastrointestinal side effects through the use of a low dose and alternate-day administration. The design of the study has previously been described in detail.14,15 In brief, between September 1992 and May 1995, letters of invitation were mailed to more than 1.7 million female health professionals. A total of 453,787 completed the questionnaires, with 65,169 initially willing and eligible to enroll. Women were eligible if they were 45 years of age or older; had no history of coronary heart disease, cerebrovascular disease, cancer (except nonmelanoma skin cancer), or other major chronic illness; had no history of side effects to any of the study medications; were not taking aspirin or nonsteroidal antiinflammatory medications (NSAIDs) more than once a week (or were willing to forego their use during the trial); were not taking anticoagulants or corticosteroids; and were not taking individual supplements of vitamin A, E, or beta carotene more than once a week. For the purposes of this study, inhibitors of cyclooxygenase, whether selective or nonselective, were considered to be NSAIDs.
Eligible women were enrolled in a three-month run-in period of placebo administration to identify a group likely to be compliant with long-term treatment. A total of 39,876 women were willing, eligible, and compliant during the run-in period and underwent randomization: 19,934 were assigned to receive aspirin and 19,942 to receive placebo. Written informed consent was obtained from all participants. The trial was approved by the institutional review board of Brigham and Women's Hospital, Boston, and was monitored by an external data and safety monitoring board.
Every 12 months, the women were sent a year's supply of monthly calendar packs containing active agents or placebo as well as questionnaires on compliance, side effects, the occurrence of relevant clinical end points, and risk factors. Study medications and end-point ascertainment were continued in a blinded fashion through the scheduled end of the trial (March 31, 2004). Follow-up and validation of reported end points were completed in February 2005. Rates of follow-up with respect to morbidity and mortality were 97.2 percent complete and 99.4 percent complete, respectively.
All the women were followed for myocardial infarction, stroke, or death from cardiovascular causes. Medical records were obtained for all women in whom a cardiovascular end point was reported to occur and were reviewed in a blinded fashion by an end-points committee of physicians. Myocardial infarction was confirmed if symptoms met World Health Organization criteria and if the event was associated with abnormal levels of cardiac enzymes or diagnostic electrocardiograms. A confirmed stroke was defined as a new neurologic deficit of sudden onset that persisted for at least 24 hours. Clinical information, computed tomographic scans, and magnetic resonance images were used to distinguish hemorrhagic from ischemic events.16 Death was confirmed to be from cardiovascular causes on the basis of an examination of autopsy reports, death certificates, medical records, and information obtained from the next of kin or other family members. The use of coronary revascularization (bypass surgery or percutaneous coronary angioplasty) was confirmed by a review of the medical records. A confirmed transient ischemic attack was defined as a neurologic deficit of sudden onset that lasted for less than 24 hours. Death from any cause was confirmed by the end-points committee or on the basis of a death certificate. Only confirmed end points were included in this analysis. For women with a reported myocardial infarction, the most common diagnoses among those in whom the diagnosis was not confirmed were stable or unstable angina or chest pain without evidence of infarction. For women with a reported stroke, the most common alternative diagnosis was transient cerebral ischemia.
Statistical Analysis
All primary analyses were performed on an intention-to-treat basis. The primary end point was a combination of major cardiovascular events, including nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular causes, and the trial was initially designed to have a statistical power of 86 percent to detect a 25 percent reduction in this end point. Secondary end points included the individual end points of fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, ischemic stroke, hemorrhagic stroke, and death from cardiovascular causes. Additional analyses included the incidence of death from any cause, transient ischemic attack, and the need for coronary revascularization. If more than one end point occurred in a given woman, only the first event within each category was counted; for the primary combined end point, the first event in each woman was counted.
Cox proportional-hazards models were used to calculate relative risks and 95 percent confidence intervals for the comparison of event rates in the aspirin and placebo groups after adjustment for age and other randomized treatment assignments (vitamin E and beta carotene, which was a component of the trial for a median of 2.1 years17). Prespecified subgroup analyses were performed according to the presence or absence of major cardiovascular risk factors. Modification of the effect of aspirin by the risk factors was assessed with the use of interaction terms between subgroup indicators and aspirin assignment, with tests for trend performed when subgroup categories were ordinal. To examine effects among women who were compliant, we performed a sensitivity analysis in which follow-up data were censored at the time a woman reported having taken less than two thirds of the study medication during the previous year. In additional analyses, data were censored on women if and when they started taking NSAIDs more than three times a month.
Results
Primary Analyses
As shown in Table 1Table 1
Baseline Characteristics of the Women., the aspirin and placebo groups were similar with respect to baseline characteristics. The average duration of follow-up from randomization to the end of the trial was 10.1 years (range, 8.2 to 10.9). At the completion of the trial, 999 women had had a first major cardiovascular event (Table 2Table 2
Incidence and Relative Risk of Confirmed Cardiovascular End Points.), for an absolute event rate of 253 per 100,000 person-years. Of these women, 477 were in the aspirin group and 522 were in the placebo group, indicating that there was a nonsignificant reduction in risk of 9 percent (relative risk, 0.91; 95 percent confidence interval, 0.80 to 1.03; P=0.13).Regarding individual end points, women in the aspirin group had a 17 percent reduction in the risk of stroke (relative risk, 0.83; 95 percent confidence interval, 0.69 to 0.99; P=0.04), as compared with women in the placebo group; a 24 percent reduction in the risk of ischemic stroke (relative risk, 0.76; 95 percent confidence interval, 0.63 to 0.93; P=0.009); and a nonsignificant increase in the risk of hemorrhagic stroke (relative risk, 1.24; 95 percent confidence interval, 0.82 to 1.87; P=0.31) (Table 2). There was no significant difference between the groups in the risk of fatal stroke (relative risk in the aspirin group, 1.04; 95 percent confidence interval, 0.58 to 1.86; P=0.90), but the aspirin group had a decreased risk of nonfatal strokes (relative risk, 0.81; 95 percent confidence interval, 0.67 to 0.97; P=0.02), as compared with the placebo group.
There was no evidence that, as compared with placebo, aspirin reduced the overall risk of myocardial infarction (relative risk, 1.02; 95 percent confidence interval, 0.84 to 1.25; P=0.83), fatal myocardial infarction (relative risk, 1.16; 95 percent confidence interval, 0.54 to 2.51; P=0.70), nonfatal myocardial infarction (relative risk, 1.01; 95 percent confidence interval, 0.83 to 1.24; P=0.90), or death from cardiovascular causes (relative risk, 0.95; 95 percent confidence interval, 0.74 to 1.22; P=0.68). However, aspirin therapy was associated with a 22 percent reduction in the risk of transient ischemic attack (relative risk, 0.78; 95 percent confidence interval, 0.64 to 0.94; P=0.01), with no significant effects on the risk of coronary revascularization (relative risk, 1.04; 95 percent confidence interval, 0.90 to 1.20; P=0.61) or death from any cause (relative risk, 0.95; 95 percent confidence interval, 0.85 to 1.06; P=0.32).
Figure 1Figure 1
Cumulative Incidence Rates of the Primary End Point of Major Cardiovascular Events. and Figure 2Figure 2Cumulative Incidence Rates of Stroke, Myocardial Infarction, Ischemic Stroke, and Hemorrhagic Stroke. present the cumulative incidence rates of major cardiovascular events, stroke, myocardial infarction, ischemic stroke, and hemorrhagic stroke according to the year of follow-up. Because it has been suggested that the ability of aspirin to inhibit platelet function diminishes over time,18 we also evaluated incidence rates according to the length of follow-up. A beneficial effect of aspirin on stroke was observed early in the trial and persisted throughout the trial, with no apparent benefit of aspirin on myocardial infarction at any point during follow-up.Neither treatment with vitamin E nor treatment with beta carotene significantly modified the effect of aspirin on the primary or secondary end points.
Subgroup Analyses
There was no evidence that any of the cardiovascular risk factors considered, except smoking status and age, modified the effect of aspirin on the primary end point of major cardiovascular events (Table 3Table 3
Incidence and Relative Risk of Cardiovascular Events, According to Baseline Characteristics.). We observed a greater benefit of aspirin on the risk of major cardiovascular events among former smokers and those who had never smoked, with an apparent increased risk among current smokers (P for interaction <0.001), although it is important to interpret this information in the context of multiple comparisons. In addition, age significantly modified the effect of aspirin on the risk of both major cardiovascular events and myocardial infarction (P for interaction = 0.05 and 0.03, respectively). The most consistent benefit of aspirin was observed among the subgroup of women 65 years of age or older at study entry; in this subgroup, the risk of major cardiovascular events was reduced by 26 percent among those who took aspirin as compared with those who took placebo (relative risk, 0.74; 95 percent confidence interval, 0.59 to 0.92; P=0.008), and the risk of ischemic stroke was reduced by 30 percent (relative risk, 0.70; 95 percent confidence interval, 0.49 to 1.00; P=0.05). This was also the only subgroup in which aspirin, as compared with placebo, significantly reduced the risk of myocardial infarction (relative risk, 0.66; 95 percent confidence interval, 0.44 to 0.97; P=0.04).To address whether compliance may have affected our results, we performed a sensitivity analysis in which follow-up data were censored at the time a woman reported having taken less than two thirds of the study medication during the preceding year. In this analysis, aspirin, as compared with placebo, reduced the risk of major cardiovascular events by 13 percent, reduced the risk of stroke by 26 percent, reduced the risk of ischemic stroke by 33 percent, and had no significant effect on the risk of myocardial infarction (relative risk, 1.03; 95 percent confidence interval, 0.81 to 1.32; P=0.79).
Some women started taking NSAIDs during the trial — a potentially important issue with respect to the risk of thrombotic events, since certain NSAIDs can compete with aspirin for receptors on platelets.19 According to our data, however, the lack of an effect of aspirin therapy on the risk of myocardial infarction was not explained by concomitant use of NSAIDs.20
Side Effects
Reports of gastrointestinal bleeding and peptic ulcer were confirmed by means of follow-up questionnaires. These side effects were significantly more common among women in the aspirin group than among women in the placebo group (Table 4Table 4
Incidence and Relative Risk of Side Effects.). There were 127 episodes of gastrointestinal bleeding requiring transfusion in the aspirin group, as compared with 91 in the placebo group (relative risk, 1.40; 95 percent confidence interval, 1.07 to 1.83; P=0.02). Self-reported hematuria, easy bruising, and epistaxis were frequent among women in both groups, with small but significant excesses among those in the aspirin group. The percentage of women reporting any symptoms suggestive of gastric upset was virtually identical in the two groups. There were five fatal gastrointestinal hemorrhages, two in the aspirin group and three in the placebo group.Discussion
In this large, placebo-controlled, primary-prevention trial involving 39,876 initially healthy women, prophylactic aspirin at a dose of 100 mg every other day was associated with a nonsignificant reduction in the risk of major cardiovascular events, a reduced risk of total stroke and of ischemic stroke, a nonsignificant increase in the risk of hemorrhagic stroke, and no significant effect on the risk of myocardial infarction or death from cardiovascular causes. With respect to the primary end point of major cardiovascular events as well as the individual end points of fatal or nonfatal stroke and myocardial infarction, consistent benefits of aspirin were observed among the subgroup of women who were 65 years of age or older. We found no evidence that menopausal status, the use or nonuse of hormone-replacement therapy after menopause, or global cardiovascular-risk status modified the effect of aspirin. As expected, the frequency of side effects related to bleeding and ulcers was increased among women who received aspirin.
Our findings must be interpreted in the context of those of other completed, randomized trials of aspirin in the primary and secondary prevention of cardiovascular disease. In secondary prevention, the Antithrombotic Trialists' Collaboration showed that aspirin clearly reduced the risk of cardiovascular events, myocardial infarction, and ischemic stroke in both men and women.1 To address the effects of aspirin in primary prevention, we performed a random-effects meta-analysis that included current data from the Women's Health Study, as well as data from five prior trials involving 55,580 participants with no history of heart disease.2-6,21 Overall, as compared with placebo, aspirin therapy significantly reduced the risk of myocardial infarction (relative risk, 0.76; 95 percent confidence interval, 0.62 to 0.95; P=0.01) but had no significant effect on the risk of stroke (relative risk, 0.97; 95 percent confidence interval, 0.83 to 1.13; P=0.69). In analyses stratified according to sex (Figure 3Figure 3
Aspirin in the Primary Prevention of Myocardial Infarction and Stroke among Men and Women.), combined data on women from the Women's Health Study, the Hypertension Optimal Treatment (HOT) study,5,21 and the Primary Prevention Project6 (and Roncaglioni MC: personal communication) indicate that aspirin therapy was associated with a significant, 19 percent reduction in the risk of stroke (relative risk, 0.81; 95 percent confidence interval, 0.69 to 0.96; P=0.01), with no reduction in the risk of myocardial infarction (relative risk, 0.99; 95 percent confidence interval, 0.83 to 1.19; P=0.95). By contrast, the aggregate data on men from the Physicians' Health Study,2 the British Doctors' Trial,3 the Thrombosis Prevention Trial,4 the HOT study,5,21 and the Primary Prevention Project6 indicate that aspirin therapy was associated with a significant, 32 percent reduction in the risk of myocardial infarction (relative risk, 0.68; 95 percent confidence interval, 0.54 to 0.86; P=0.001) and a nonsignificant increase in the risk of stroke (relative risk, 1.13; 95 percent confidence interval, 0.96 to 1.33; P=0.15). The differences between men and women were significant at the P=0.01 level for myocardial infarction and at the P=0.005 level for stroke.The reasons for any sex-based differences in the efficacy of aspirin for primary prevention are unclear and require further exploration. Although the observed reductions in the risk of stroke could be due to chance, the reduced risk of transient ischemic attack associated with aspirin therapy adds support to the possibility of a causal interpretation. We cannot rule out the possibility that our null finding for the risk of myocardial infarction in women was due to an insufficient dose of aspirin or to the alternate-day regimen. However, we believe these explanations to be unlikely for three reasons.
First, we have previously shown that the dose of 100 mg every other day used in the Women's Health Study reduces thromboxane levels by 93 percent and prostacyclin levels by 85 percent and that these effects are similar in men and women.22 Second, in the HOT study, a 75-mg daily dose of aspirin significantly lowered the risk of myocardial infarction overall, with a 42 percent reduction in the risk among men but a far smaller and nonsignificant reduction among women.21 Third, since the dose and alternate-day regimen of aspirin used in our study were adequate to lower the risk of stroke, it is unlikely that any hypothesized sex-based differences in the resistance to aspirin were at play overall. However, resistance to aspirin may be more prevalent among smokers,23 and this resistance may have played some role in the increased risk with aspirin observed among current smokers. We also believe it unlikely that a reduction in the efficacy of aspirin over time is a viable explanation, since the cumulative incidence data presented in Figure 1 and Figure 2 offer no support for this hypothesis. Furthermore, suboptimal compliance is an unlikely explanation, since aspirin did not decrease the risk of myocardial infarction among women with high rates of compliance — an observation again in contrast to data on stroke among the same women.
With regard to daily clinical practice, our data demonstrate that aspirin therapy was associated with a net reduction in the risk of stroke among women, with a reduction in the risk of the far more common ischemic stroke and an increase in the risk of hemorrhagic stroke. This observation is particularly relevant, since as compared with men, women have a relatively greater proportion of strokes than of myocardial infarctions. Among women in the placebo group, there were more strokes than myocardial infarctions (266 vs. 193), and thus, the ratio of incident strokes to incident myocardial infarctions was 1.4:1, as compared with the ratio of 0.4:1 among men in the Physicians' Health Study.2 From a policy perspective, our findings clearly demonstrate the importance of studying women as well as men in major cardiovascular clinical trials.
An interesting finding in our subgroup analyses was that the most consistent benefit of aspirin was observed among women 65 years of age or older. This group of 4097 women composed 10 percent of the study population yet had almost one third of the cardiovascular events. In this group, aspirin use, as compared with placebo use, led to 44 fewer myocardial infarctions, strokes, or deaths from cardiovascular causes (P=0.008) but to 16 more gastrointestinal hemorrhages requiring transfusion (P=0.05), emphasizing, as with any agent, the importance of balancing benefits and risks. This age-based difference deserves further investigation.
With respect to guidelines in primary prevention, in 2002, the Preventive Services Task Force24 and the American Heart Association9 recommended aspirin for adults whose 10-year risks of a first coronary-heart-disease event were at least 6 percent and 10 percent, respectively. However, this may be complex for women, since in our study overall, aspirin lowered the risk of stroke without affecting the risk of myocardial infarction or death from cardiovascular causes. Thus, as with men, any decision about the use of aspirin in primary prevention among women must ultimately be made after a woman consults her physician or health care provider, so that the net absolute benefits and risks for the individual patient can be ascertained.
Supported by grants (HL-43851 and CA-47988) from the National Heart, Lung, and Blood Institute and the National Cancer Institute, Bethesda, Md. Aspirin and aspirin placebo were provided by Bayer HealthCare. Vitamin E and vitamin E placebo were provided by the Natural Source Vitamin E Association.
Dr. Ridker reports having received grant support from Bayer. Dr. Cook reports having served as a consultant to Bayer. Dr. Gaziano reports having served as a consultant to, and receiving grant support from, Bayer and McNeil. Dr. Hennekens reports having served as a consultant to Bayer and McNeil and receiving grant support from Bayer.
This article was published at www.nejm.org on March 7, 2005.
We are indebted to the 39,876 participants in the Women's Health Study for their dedicated and conscientious collaboration; to the entire staff of the Women's Health Study, under the leadership of David Gordon, Maria Andrade, Susan Burt, Mary Breen, Marilyn Chown, Lisa Fields-Johnson, Georgina Friedenberg, Inge Judge, Jean MacFadyen, Geneva McNair, Laura Pestana, David Potter, Philomena Quinn, Claire Ridge, Fred Schwerin, and Harriet Samuelson; to Christine Albert, Michelle Albert, Gavin Blake, Claudia Chae, Wendy Chen, Richard Doll, Carlos Kase, Tobias Kurth, Richard Peto, Aruna Pradhan, Kathryn Rexrode, Bernard Rosner, and H. Jacqueline Suk for their assistance in the design and conduct of the trial; and especially to James Taylor for chairing the end-points committee.
Source Information
From the Divisions of Preventive Medicine (P.MR., N.R.C., I-M.L., D.G., J.M.G., J.E.M., J.E.B.), Cardiovascular Medicine (P.MR., J.M.G.), and Aging (J.M.G., J.E.B.), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; the Department of Epidemiology, Harvard School of Public Health (P.MR., N.R.C., I-M.L., J.E.M., J.E.B.); Veterans Affairs Boston Healthcare System (J.M.G.); and the Department of Ambulatory Care and Prevention, Harvard Medical School (J.E.B.) — all in Boston; and the Departments of Medicine and Epidemiology and Public Health, University of Miami School of Medicine, and the Department of Biomedical Science, Center of Excellence, Florida Atlantic University, Miami (C.H.H.).
Address reprint requests to Dr. Buring at the Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Ave. East, Boston, MA 02215, or at jburing@rics.bwh.harvard.edu.
Appendix
Members of the data and safety monitoring board included L. Cohen, R. Collins, T. Colton, D. DeMets, I.C. Henderson, A. La Croix, R. Prentice, and N. Wenger (chair) and M.F. Cotch, F. Ferris, L. Friedman, P. Greenwald, N. Kurinij, M. Perloff, E. Schron, and A. Zonderman (ex officio members).
- References
References
1
Antithrombotic Trialists' Collaboration
CrossRef | Web of Science2
Steering Committee of the Physicians' Health Study Research Group
Full Text | Web of Science | Medline3
Peto R ,Gray R ,Collins R , et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296:313-316
CrossRef | Web of Science | Medline4
The Medical Research Council's General Practice Research Framework
CrossRef | Web of Science | Medline5
Hansson L ,Zanchetti A ,Carruthers SG , et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762
CrossRef | Web of Science | Medline6
Collaborative Group of the Primary Prevention Project
CrossRef | Web of Science | Medline7
Eidelman RS ,Hebert PR ,Weisman SE ,Hennekens CH . An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-2010
CrossRef | Web of Science | Medline8
Hayden M ,Pignone M ,Phillips C ,Mulrow C . Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-172
Web of Science | Medline9
Pearson TA ,Blair SN ,Daniels SR , et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-391
CrossRef | Web of Science | Medline10
Mosca L ,Appel LJ ,Benjamin EJ , et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-693
CrossRef | Medline11
Montgomery PR ,Berger LG ,Mitenko PA ,Sitar DS . Salicylate metabolism: effects of age and sex in adults. Clin Pharmacol Ther 1986;39:571-576
CrossRef | Web of Science | Medline12
Manson JE ,Hsia J ,Johnson KC , et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534
Full Text | Web of Science | Medline13
Rodondi N ,Bauer DC . Assessing the risk/ benefit profile before recommending aspirin for the primary prevention of cardiovascular events. Am J Med 2004;117:528-530
CrossRef | Web of Science | Medline14
Buring JE ,Hennekens CH . The Women's Health Study: summary of the study design. J Myocard Ischemia 1992;4:27-2915
Rexrode KM ,Lee IM ,Cook NR ,Hennekens CH ,Buring JE . Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med 2000;9:19-27
CrossRef | Medline16
Atiya M ,Kurth T ,Berger K ,Buring JE ,Kase CS . Interobserver agreement in the classification of stroke in the Women's Health Study. Stroke 2003;34:565-567
CrossRef | Web of Science | Medline17
Lee I-M ,Cook NR ,Manson JE ,Buring JE ,Hennekens CH . β-Carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999;91:2102-2106
CrossRef | Web of Science | Medline18
Pulcinelli FM ,Pignatelli P ,Celestini A ,Riondino S ,Gazzaniga PP ,Violi F . Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004;43:979-984
CrossRef | Web of Science | Medline19
Catella-Lawson F ,Reilly MP ,Kapoor SC , et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817
Full Text | Web of Science | Medline20
Kurth T ,Glynn RJ ,Walker AM , et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003;108:1191-1195
CrossRef | Web of Science | Medline21
Kjeldsen SE ,Kolloch RE ,Leonetti G , et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid: the HOT study. J Hypertens 2000;18:629-642
CrossRef | Web of Science | Medline22
Ridker PM ,Hennekens CH ,Tofler GH ,Lipinska I ,Buring JE . Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk 1996;3:209-212
CrossRef | Medline23
Sanderson S ,Emery J ,Baglin T ,Kinmonth A-L . Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005;142:370-380
Web of Science | Medline24
Preventive Services Task Force
Web of Science | Medline
- Citing Articles (421)
Citing Articles
1
Marcia Dewi Hartanto, Zita Arieselia, Rianto Setiabudy, Arini Setiawati, Ali Baziad. (2012) Urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin-F1α in healthy post-menopausal and pre-menopausal women receiving aspirin 100 mg. Journal of Thrombosis and Thrombolysis
CrossRef2
Cathleen M. Rivera, Juhee Song, Laurel Copeland, Chris Buirge, Marcia Ory, Catherine J. McNeal. (2012) Underuse of Aspirin for Primary and Secondary Prevention of Cardiovascular Disease Events in Women. Journal of Women's Health120203083701003
CrossRef3
Benjamin T. Bikman. (2012) A role for sphingolipids in the pathophysiology of obesity-induced inflammation. Cellular and Molecular Life Sciences
CrossRef4
William J. Kostis, Jerry Q. Cheng, Jeanne M. Dobrzynski, Javier Cabrera, John B. Kostis. (2012) Meta-Analysis of Statin Effects in Women Versus Men. Journal of the American College of Cardiology 59:6, 572-582
CrossRef5
Giovanni Davì, Natale Vazzana, Simona Sestili. (2012) Variability in the response to antiplatelet treatment in diabetes mellitus. Prostaglandins & Other Lipid Mediators
CrossRef6
Enma V. Paez Espinosa, John P. Murad, Fadi T. Khasawneh. (2012) Aspirin: Pharmacology and Clinical Applications. Thrombosis 2012, 1-15
CrossRef7
Yuxiang Dai, Junbo Ge. (2012) Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease. Thrombosis 2012, 1-7
CrossRef8
Gundu H. R. Rao, Jawad Fareed. (2012) Aspirin Prophylaxis for the Prevention of Thrombosis: Expectations and Limitations. Thrombosis 2012, 1-9
CrossRef9
Kathryn A. Britton, I-Min Lee, Lu Wang, J. Michael Gaziano, JoAnn E. Manson, Julie E. Buring, Howard D. Sesso. (2011) Physical Activity and the Risk of Becoming Overweight or Obese in Middle-Aged and Older Women. Obesity
CrossRef10
Paul A. Gurbel, Udaya S. Tantry. 2011. Resistance to Antiplatelet Therapy. .
CrossRef11
Karin Mauer, Jorge F. Saucedo. 2011. Cardiology-In-Depth Look: Advances in Antiplatelet Therapy. .
CrossRef12
J. A. N. Dorresteijn, F. L. J. Visseren, P. M. Ridker, N. P. Paynter, A. M. J. Wassink, J. E. Buring, Y. van der Graaf, N. R. Cook. (2011) Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. European Heart Journal 32:23, 2962-2969
CrossRef13
Maria Czarina Acelajado, Suzanne Oparil. (2011) Antiplatelet Therapy for Transient Ischemic Attack. The Journal of Clinical Hypertensionno-no
CrossRef14
K. C. Fitzgerald, S. E. Chiuve, J. E. Buring, P. M. Ridker, R. J. Glynn. (2011) Comparison of Associations of Adherence to a Dietary Approaches to Stop Hypertension (DASH)-style Diet With Risks of Cardiovascular Disease and Venous Thromboembolism. Journal of Thrombosis and Haemostasisno-no
CrossRef15
Susana Novella, Ana Paula Dantas, Gloria Segarra, Laura Novensa, Magda Heras, Carlos Hermenegildo, Pascual Medina. (2011) Aging enhances contraction to thromboxane A2 in aorta from female senescence-accelerated mice. AGE
CrossRef16
Dipan A. Desai, Sammy Zakaria, Pamela Ouyang. (2011) Initiation of Statin Therapy: Are There Age Limits?. Current Atherosclerosis Reports
CrossRef17
Brian K Irons. (2011) Diagnosis of diabetes mellitus as a cardiovascular risk equivalent or risk factor and implications in drug therapy management. Diabetes Management 1:6, 615-626
CrossRef18
Scot H. Simpson, John-Michael Gamble, Laurie Mereu, Thane Chambers. (2011) Effect of Aspirin Dose on Mortality and Cardiovascular Events in People with Diabetes: A Meta-Analysis. Journal of General Internal Medicine 26:11, 1336-1344
CrossRef19
Flavia Franconi, Ciriaco Carru, Ilaria Spoletini, Walter Malorni, Stefano Vella, Giuseppe Mercuro, Martino Deidda, Giuseppe Rosano. (2011) A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. Therapeutic Delivery 2:11, 1437-1453
CrossRef20
Kyle Grieve, Sheri L. Koshman, Glen J. Pearson, William M. Semchuk, Raj Padwal, Ann Thompson. (2011) Low-dose ASA use for primary prevention of cardiovascular disease in patients without diabetes: When should you recommend it? A case-based approach. Canadian Pharmacists Journal 144:6, 278-286.e1
CrossRef21
Nanette K. Wenger. (2011) Coronary Heart Disease in Men and Women: Does 1 Size Fit All? No!. Clinical Cardiology 34:11, 663-667
CrossRef22
Roopinder K. Sandhu, Tobias Kurth, David Conen, Nancy R. Cook, Paul M. Ridker, Christine M. Albert. (2011) Relation of Renal Function to Risk for Incident Atrial Fibrillation in Women. The American Journal of Cardiology
CrossRef23
Yahaya Hassan, Samah W. Al-Jabi, Noorizan Abd Aziz, Irene Looi. (2011) Impact of the Additive Effect of Angiotensin-Converting Enzyme Inhibitors and/or Statins with Antiplatelet Medication on Mortality after Acute Ischaemic Stroke. Basic & Clinical Pharmacology & Toxicologyno-no
CrossRef24
Nathaniel S. Rial, Kwan Choi, Tam Nguyen, Branden Snyder, Marvin J. Slepian. (2011) Nuclear factor kappa B (NF-κB): A novel cause for diabetes, coronary artery disease and cancer initiation and promotion?. Medical Hypotheses
CrossRef25
JoAnn E. Manson, Shari S. Bassuk, I-Min Lee, Nancy R. Cook, Michelle A. Albert, David Gordon, Elaine Zaharris, Jean G. MacFadyen, Eleanor Danielson, Jennifer Lin, Shumin M. Zhang, Julie E. Buring. (2011) The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials
CrossRef26
R. S. Scotland, M. J. Stables, S. Madalli, P. Watson, D. W. Gilroy. (2011) Sex-differences in resident immune cell phenotype underlies more efficient acute inflammatory responses in female mice. Blood
CrossRef27
Mayurkumar D Bhakta, Farouk Mookadam, Susan Wilansky. (2011) Cardiovascular disease in women. Future Cardiology 7:5, 613-627
CrossRef28
David R. Holmes, Jeffrey A. Becker, Christopher B. Granger, Marian C. Limacher, Robert Lee Page, Cathy Sila, Joseph P. Drozda, Joseph G. Cacchione, Blair D. Erb, Robert A. Harrington, Jerry D. Kennett, Harlan M. Krumholz, Frederick A. Masoudi, Eric D. Peterson, Athena Poppas, David J. Sahn, Mark L. Sanz, David M. Shahian, John R. Windle, Janet F. Wyman. (2011) ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution. Journal of the American College of Cardiology 58:12, 1287-1307
CrossRef29
Nanette K. Wenger. (2011) What Do the 2011 American Heart Association Guidelines Tell Us About Prevention of Cardiovascular Disease in Women?. Clinical Cardiology 34:9, 520-523
CrossRef30
Fadi B. Nahab, Sakib Qureshi. 2011. Antithrombotics for Ischemic Stroke. , 205-222.
CrossRef31
Esther S.H. Kim, Thomas P. Carrigan, Venu Menon. (2011) International Participation in Cardiovascular Randomized Controlled Trials Sponsored by the National Heart, Lung, and Blood Institute. Journal of the American College of Cardiology 58:7, 671-676
CrossRef32
X. Garcia-Albeniz, A.T. Chan. (2011) Aspirin for the prevention of colorectal cancer. Best Practice & Research Clinical Gastroenterology 25:4-5, 461-472
CrossRef33
Donna Shoupe. (2011) Individualizing hormone therapy to minimize risk: accurate assessment of risks and benefits. Women's Health 7:4, 475-485
CrossRef34
Melinda B Davis, Claire S Duvernoy. (2011) How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women. Women's Health 7:4, 433-451
CrossRef35
Nina Raju, Magdalena Sobieraj-Teague, Jack Hirsh, Martin O'Donnell, John Eikelboom. (2011) Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease. The American Journal of Medicine 124:7, 621-629
CrossRef36
Jennifer A. Frontera, Natalia Egorova, Alan J. Moskowitz. (2011) National trend in prevalence, cost, and discharge disposition after subdural hematoma from 1998–2007*. Critical Care Medicine 39:7, 1619-1625
CrossRef37
Jeffrey S. Berger, Anuradha Lala, Mori J. Krantz, Gizelle S. Baker, William R. Hiatt. (2011) Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials. American Heart Journal 162:1, 115-124.e2
CrossRef38
Deren Wang, Zilong Hao, Wendan Tao, Fanyi Kong, Shihong Zhang, Bo Wu, Sen Lin, Ming Liu. (2011) Acute ischemic stroke in the very elderly Chinese: Risk factors, hospital management and one-year outcome. Clinical Neurology and Neurosurgery 113:6, 442-446
CrossRef39
A. H. E. M. Maas, Y. T. van der Schouw, V. Regitz-Zagrosek, E. Swahn, Y. E. Appelman, G. Pasterkamp, H. ten Cate, P. M. Nilsson, M. V. Huisman, H. C. G. Stam, K. Eizema, M. Stramba-Badiale. (2011) Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: Proceedings of the Workshop held in Brussels on Gender Differences in Cardiovascular disease, 29 September 2010. European Heart Journal 32:11, 1362-1368
CrossRef40
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, Alexander G.G. Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology 27:3, S1-S59
CrossRef41
Takashi Furuno, Fumiyasu Yamasaki, Takeshi Yokoyama, Kyoko Sato, Takayuki Sato, Yoshinori Doi, Tetsuro Sugiura. (2011) Effects of various doses of aspirin on platelet activity and endothelial function. Heart and Vessels 26:3, 267-273
CrossRef42
Edward S. Huang, Lisa L. Strate, Wendy W. Ho, Salina S. Lee, Andrew T. Chan. (2011) Long-Term Use of Aspirin and the Risk of Gastrointestinal Bleeding. The American Journal of Medicine 124:5, 426-433
CrossRef43
Eric E Adelman, Lynda Lisabeth, Devin L Brown. (2011) Gender differences in the primary prevention of stroke with aspirin. Women's Health 7:3, 341-353
CrossRef44
Monica Acciarresi, Paola De Rango, Francesca Romana Pezzella, Paola Santalucia, Serena Amici, Maurizio Paciaroni, Valeria Mommi, Giancarlo Agnelli, Valeria Caso. (2011) Secondary stroke prevention in women. Women's Health 7:3, 391-397
CrossRef45
Richard FitzGerald, Munir Pirmohamed. (2011) Aspirin resistance: Effect of clinical, biochemical and genetic factors. Pharmacology & Therapeutics 130:2, 213-225
CrossRef46
Valeria Caso, Helmi L Lutsep. (2011) A focus on stroke in women. Women's Health 7:3, 257-259
CrossRef47
Jennifer A. Frontera, Kenneth Reyes, Errol Gordon, Arjun Gowda, Christina Grilo, Natalia Egorova, Aman Patel, Joshua B. Bederson. (2011) Trend in Outcome and Financial Impact of Subdural Hemorrhage. Neurocritical Care 14:2, 260-266
CrossRef48
Ann I. Scher, David W. Dodick. 2011. Cardiovascular Disorders. , 27-40.
CrossRef49
Stephen G. Ellis, Mehdi H. Shishehbor, Samir R. Kapadia, A. Michael Lincoff, Ravi Nair, Patrick L. Whitlow, Christopher T. Bajzer, Leslie L. Cho, E. Murat Tuzcu, Russell Raymond, Patrick Vargo, Rebecca Cunningham, Sandra J. Dushman-Ellis. (2011) Enhanced Prediction of Mortality After Percutaneous Coronary Intervention by Consideration of General and Neurological Indicators. JACC: Cardiovascular Interventions 4:4, 442-448
CrossRef50
Stalo Karageorgi, Monica McGrath, I-Min Lee, Julie Buring, Peter Kraft, Immaculata De Vivo. (2011) Polymorphisms in genes hydroxysteroid-dehydrogenase-17b type 2 and type 4 and endometrial cancer risk. Gynecologic Oncology 121:1, 54-58
CrossRef51
Tobias Kurth, Hans-Christoph Diener. 2011. Migraine and Stroke. , 14-26.
CrossRef52
Howard N. Hodis, Wendy J. Mack. (2011) A “window of opportunity:” The reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Research 1379, 244-252
CrossRef53
Nancy R. Cook, Nina P. Paynter. (2011) Performance of reclassification statistics in comparing risk prediction models. Biometrical Journal 53:2, 237-258
CrossRef54
Lori Mosca, Emelia J. Benjamin, Kathy Berra, Judy L. Bezanson, Rowena J. Dolor, Donald M. Lloyd-Jones, L. Kristin Newby, Ileana L. Piña, Véronique L. Roger, Leslee J. Shaw, Dong Zhao, Theresa M. Beckie, Cheryl Bushnell, Jeanine D'Armiento, Penny M. Kris-Etherton, Jing Fang, Theodore G. Ganiats, Antoinette S. Gomes, Clarisa R. Gracia, Constance K. Haan, Elizabeth A. Jackson, Debra R. Judelson, Ellie Kelepouris, Carl J. Lavie, Anne Moore, Nancy A. Nussmeier, Elizabeth Ofili, Suzanne Oparil, Pamela Ouyang, Vivian W. Pinn, Katherine Sherif, Sidney C. Smith, George Sopko, Nisha Chandra-Strobos, Elaine M. Urbina, Viola Vaccarino, Nanette K. Wenger. (2011) Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update. Journal of the American College of Cardiology 57:12, 1404-1423
CrossRef55
Kathryn A. Britton, Aruna D. Pradhan, J. Michael Gaziano, JoAnn E. Manson, Paul M. Ridker, Julie E. Buring, Howard D. Sesso. (2011) Hemoglobin A1c, Body Mass Index, and the Risk of Hypertension in Women. American Journal of Hypertension 24:3, 328-334
CrossRef56
Medha Barbhaiya, Doruk Erkan. (2011) Primary Thrombosis Prophylaxis in Antiphospholipid Antibody–Positive Patients: Where Do We Stand?. Current Rheumatology Reports 13:1, 59-69
CrossRef57
I.-M. Lee, N. R. Cook, N. A. Shadick, E. Pereira, J. E. Buring. (2011) Prospective cohort study of breast implants and the risk of connective-tissue diseases. International Journal of Epidemiology 40:1, 230-238
CrossRef58
Ada Stefanescu, Stephen D. Wiviott. (2011) Considerations Regarding Antiplatelet Therapy in the Elderly. Current Cardiovascular Risk Reports 5:1, 86-95
CrossRef59
Monica McGrath, I-Min Lee, Julie Buring, Immaculata De Vivo. (2011) Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. Gynecologic Oncology 120:2, 174-178
CrossRef60
Amytis Towfighi, Daniela Markovic, Bruce Ovbiagele. (2011) Persistent Sex Disparity in Midlife Stroke Prevalence in the United States. Cerebrovascular Diseases 31:4, 322-328
CrossRef61
John Burn. (2011) Chemoprevention. Viszeralmedizin 27:4, 322-328
CrossRef62
Colin F. Galloway, John C. Stevenson. (2011) Aspirin in the primary prevention of cardiovascular disease. Maturitas 68:1, 3-4
CrossRef63
A. C. MAUER, N. A. KHAZANOV, N. LEVENKOVA, S. TIAN, E. M. BARBOUR, C. KHALIDA, J. N. TOBIN, B. S. COLLER. (2011) Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. Journal of Thrombosis and Haemostasis 9:1, 100-108
CrossRef64
Stavros Stavrakis, Julie A. Stoner, Madona Azar, Siddharth Wayangankar, Udho Thadani. (2011) Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis. The American Journal of the Medical Sciences 341:1, 1-9
CrossRef65
Robert Y.L. Zee, Paul M Ridker, Daniel I. Chasman. (2011) Genetic variants in eleven telomere-associated genes and the risk of incident cardio/cerebrovascular disease: The Women's Genome Health Study. Clinica Chimica Acta 412:1-2, 199-202
CrossRef66
Jennifer E Ho, Daniel Levy, Lynda Rose, Andrew D Johnson, Paul M Ridker, Daniel I Chasman. (2011) Discovery and replication of novel blood pressure genetic loci in the Womenʼs Genome Health Study. Journal of Hypertension 29:1, 62-69
CrossRef67
Brittany Folks, William G LeBlanc, Elizabeth W Staton, Wilson D Pace. (2011) Reconsidering low-dose aspirin therapy for cardiovascular disease: a study protocol for physician and patient behavioral change. Implementation Science 6:1, 65
CrossRef68
Robert Y.L. Zee, Paul M Ridker, Daniel I. Chasman. (2011) Mitochondrial uncoupling protein gene cluster variation (UCP2–UCP3) and the risk of incident type 2 diabetes mellitus: The Women's Genome Health Study. Atherosclerosis 214:1, 107-109
CrossRef69
Emily G. Kurtz, Paul M. Ridker, Lynda M. Rose, Nancy R. Cook, Brendan M. Everett, Julie E. Buring, Kathryn M. Rexrode. (2011) Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes. Menopause 18:1, 23-29
CrossRef70
Sonia Butalia, Alexander A Leung, William A Ghali, Doreen M Rabi. (2011) Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovascular Diabetology 10:1, 25
CrossRef71
Y. B
jot, M. Giroud, E. Touz
CrossRef72
Massimo F.L. Pomponi, Giovanni Gambassi, Massimiliano Pomponi, Annamaria Di Gioia, Carlo Masullo. (2011) Why docosahexaenoic acid and aspirin supplementation could be useful in women as a primary prevention therapy against Alzheimer's disease?. Ageing Research Reviews 10:1, 124-131
CrossRef73
Mar Castellanos, Babette B. Weksler, Oscar R. Benavente. 2011. Antiplatelet Therapy for Secondary Prevention of Stroke. , 1147-1172.
CrossRef74
Larry B. Goldstein, Ralph L. Sacco. 2011. Primary Prevention of Stroke. , 242-251.
CrossRef75
Olivia I. Okereke, JoAnn E. Manson. 2011. The VITamin D and OmegA-3 TriaL (VITAL). , 2043-2055.
CrossRef76
Lionel D. Edwards. 2010. Drug Development Research in Women. , 207-225.
CrossRef77
Berrington de Gonzalez, Amy, Hartge, Patricia, Cerhan, James R., Flint, Alan J., Hannan, Lindsay, MacInnis, Robert J., Moore, Steven C., Tobias, Geoffrey S., Anton-Culver, Hoda, Freeman, Laura Beane, Beeson, W. Lawrence, Clipp, Sandra L., English, Dallas R., Folsom, Aaron R., Freedman, D. Michal, Giles, Graham, Hakansson, Niclas, Henderson, Katherine D., Hoffman-Bolton, JudithHoppin, Jane A., Koenig, Karen L., Lee, I-Min, Linet, Martha S., Park, Yikyung, Pocobelli, Gaia, Schatzkin, Arthur, Sesso, Howard D., Weiderpass, Elisabete, Willcox, Bradley J., Wolk, Alicja, Zeleniuch-Jacquotte, Anne, Willett, Walter C., Thun, Michael J., . (2010) Body-Mass Index and Mortality among 1.46 Million White Adults. New England Journal of Medicine 363:23, 2211-2219
Full Text78
Christine Cole Johnson, Richard B Hayes, Robert E Schoen, Marc J Gunter, Wen-Yi Huang. (2010) Non-Steroidal Anti-Inflammatory Drug Use and Colorectal Polyps in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. The American Journal of Gastroenterology 105:12, 2646-2655
CrossRef79
I. S. Mackenzie, M. W. H. Coughtrie, T. M. MacDonald, L. Wei. (2010) Antiplatelet drug interactions. Journal of Internal Medicine 268:6, 516-529
CrossRef80
N. R. Cook. (2010) Methods for evaluating novel biomarkers - a new paradigm. International Journal of Clinical Practice 64:13, 1723-1727
CrossRef81
I. A. Scott, P. B. Greenberg. (2010) Cautionary tales in the interpretation of studies of tools for predicting risk and prognosis. Internal Medicine Journal 40:12, 803-812
CrossRef82
Debby Keuken, Patrick Bindels, Niek Klazinga, Joke Haafkens. (2010) A systematic approach for uptake of evidence on sex-specific issues in guidelines - a pilot study. Journal of Evaluation in Clinical Practiceno-no
CrossRef83
Michael Pignone, Craig D. Williams. (2010) Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nature Reviews Endocrinology 6:11, 619-628
CrossRef84
Arthur E. Fass. (2010) Chronic Coronary Disease in the Post-COURAGE Era. Cardiology in Review 18:6, 292-297
CrossRef85
Guillaume Cayla, Jean-Philippe Collet, Johanne Silvain, Gérard Thiefin, France Woimant, Gilles Montalescot. (2010) Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey. International Journal of Cardiology
CrossRef86
Chunyan He, Peter Kraft, Daniel I. Chasman, Julie E. Buring, Constance Chen, Susan E. Hankinson, Guillaume Paré, Stephen Chanock, Paul M. Ridker, David J. Hunter. (2010) A large-scale candidate gene association study of age at menarche and age at natural menopause. Human Genetics 128:5, 515-527
CrossRef87
P. A. Ringleb, M.-G. Bousser, G. Ford, P. Bath, M. Brainin, V. Caso, Á. Cervera, A.l Chamorro, Charlotte Cordonnier, L. Csiba, A. Davalos, H.-C. Diener, J. Ferro, W. Hacke, M. Hennerici, M. Kaste, P. Langhorne, K. Lees, D. Leys, J. Lodder, H. S. Markus, J.-L. Mas, H. P. Mattle, K. Muir, B. Norrving, V. Obach, S. Paolucci, E. B. Ringelstein, P. D. Schellinger, J. Sivenius, V. Skvortsova, K. Stibrant Sunnerhagen, L. Thomassen, D. Toni, R.r von Kummer, N. Gunnar Wahlgren, M. F. Walker, J. Wardlaw. 2010. Ischaemic Stroke and Transient Ischaemic Attack. , 101-158.
CrossRef88
Yonghong Li, Olga A. Iakoubova, Dov Shiffman, James J. Devlin, James S. Forrester, H. Robert Superko. (2010) KIF6 Polymorphism as a Predictor of Risk of Coronary Events and of Clinical Event Reduction by Statin Therapy. The American Journal of Cardiology 106:7, 994-998
CrossRef89
Stephanie C. Manson, Agnes Benedict, Feng Pan, Kim U. Wittrup-Jensen, A. Mark Fendrick. (2010) Potential economic impact of increasing low dose aspirin usage on CVD in the US. Current Medical Research and Opinion 26:10, 2365-2373
CrossRef90
Jun Li, Sharon E. Benashski, Chad Siegel, Fudong Liu, Louise D. McCullough. (2010) Adenosine monophosphate activated protein kinase inhibition is protective in both sexes after experimental stroke. Neuroscience Letters 482:1, 62-65
CrossRef91
Samuel Chackalamannil. 2010. Antiplatelet Agents. .
CrossRef92
Helen Y. Lee, Yvette P. Tong, Shan Xing, Catherine E. Cooke. (2010) Aspirin use in elderly women receiving medication therapy management services. Advances in Therapy 27:9, 613-622
CrossRef93
F. Malekzadeh, T. Marshall, A. Pourshams, M. Gharravi, A. Aslani, A. Nateghi, M. Rastegarpanah, M. Khoshnia, S. Semnani, R. Salahi, G. N. Thomas, B. Larijani, K. K. Cheng, R. Malekzadeh. (2010) A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. International Journal of Clinical Practice 64:9, 1220-1227
CrossRef94
Larry B Goldstein. (2010) Physical activity and the risk of stroke. Expert Review of Neurotherapeutics 10:8, 1263-1265
CrossRef95
R. D. Langer. (2010) On the need to clarify and disseminate contemporary knowledge of hormone therapy initiated near menopause. Climacteric 13:4, 303-306
CrossRef96
Colum F. Amory, Jesse Weinberger. 2010. Cerebrovascular Disease. , 698-709.
CrossRef97
D. Conen, P. M. Ridker, B. M. Everett, U. B. Tedrow, L. Rose, N. R. Cook, J. E. Buring, C. M. Albert. (2010) A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. European Heart Journal 31:14, 1730-1736
CrossRef98
Dara G. Jamieson, Maryna Skliut. (2010) Stroke in Women: What is Different?. Current Atherosclerosis Reports 12:4, 236-243
CrossRef99
Carlos G. Santos-Gallego, Jeremías Bayón, Juan José Badimón. (2010) Thrombi of Different Pathologies: Implications for Diagnosis and Treatment. Current Treatment Options in Cardiovascular Medicine 12:3, 274-291
CrossRef100
Michael Pignone, Mark J. Alberts, John A. Colwell, Mary Cushman, Silvio E. Inzucchi, Debabrata Mukherjee, Robert S. Rosenson, Craig D. Williams, Peter W. Wilson, M. Sue Kirkman. (2010) Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. Journal of the American College of Cardiology 55:25, 2878-2886
CrossRef101
C. Noel Bairey Merz, Saralyn Mark, Barbara D. Boyan, Alice K. Jacobs, Prediman K. Shah, Leslee J. Shaw, Doris Taylor, Eduardo Marbán. (2010) Proceedings from the Scientific Symposium: Sex Differences in Cardiovascular Disease and Implications for Therapies. Journal of Women's Health 19:6, 1059-1072
CrossRef102
Markus Schürks, Julie E. Buring, Tobias Kurth. (2010) Migraine, Migraine Features, and Cardiovascular Disease. Headache: The Journal of Head and Face Pain 50:6, 1031-1040
CrossRef103
William G. Christen, Robert J. Glynn, Emily Y. Chew, Julie E. Buring. (2010) Vitamin E and Age-Related Macular Degeneration in a Randomized Trial of Women. Ophthalmology 117:6, 1163-1168
CrossRef104
P.M. Mannucci. (2010) Aspirin as antiplatelet agent in diabetes: Cons. European Journal of Internal Medicine 21:3, 154-156
CrossRef105
William E. Boden, Marcus D. Flather, Deepak L. Bhatt. (2010) Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective. Cardiovascular Drugs and Therapy 24:3, 207-216
CrossRef106
Sergio Coccheri. (2010) Antiplatelet Drugs – Do We Need New Options?. Drugs 70:7, 887-908
CrossRef107
Patricia A. Howard. (2010) Cardiovascular Therapeutics - Is Aspirin Really Effective for Primary Cardiovascular Prevention?. Hospital Pharmacy 45:5, 362-366
CrossRef108
Ruo-Li Chen, Joyce S. Balami, Margaret M. Esiri, Liang-Kung Chen, Alastair M. Buchan. (2010) Ischemic stroke in the elderly: an overview of evidence. Nature Reviews Neurology 6:5, 256-265
CrossRef109
Alison L. Bailey, Charles L. Campbell, Susan S. Smyth. (2010) Aspirin for the Primary Prevention of Cardiovascular Disease in Women. Current Cardiovascular Risk Reports 4:3, 209-215
CrossRef110
Nancy A. Shadick, Elizabeth W. Karlson, Nancy R. Cook, Nancy E. Maher, Julie E. Buring, I-Min Lee. (2010) Low-dose aspirin in the primary prevention of rheumatoid arthritis: The women's health study. Arthritis Care & Research 62:4, 545-550
CrossRef111
Emer M Smyth. (2010) Thromboxane and the thromboxane receptor in cardiovascular disease. Clinical Lipidology 5:2, 209-219
CrossRef112
S. SCHULMAN, F. A. SPENCER. (2010) Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. Journal of Thrombosis and Haemostasis 8:4, 641-650
CrossRef113
James M. Gebel. (2010) Heterogeneity of Efficacy and Safety of Antiplatelet Therapy in Cardiovascular and Cerebrovascular Disease. American Journal Cardiovascular Drugs 10:2, 115-124
CrossRef114
Jeffrey S. Berger, Courtney O. Jordan, Donald Lloyd-Jones, Roger S. Blumenthal. (2010) Screening for Cardiovascular Risk in Asymptomatic Patients. Journal of the American College of Cardiology 55:12, 1169-1177
CrossRef115
Sarah Bristol-Gould, Michelle Desjardins, Teresa K Woodruff. (2010) The Illinois Women’s Health Registry: advancing women’s health research and education in Illinois, USA. Women's Health 6:2, 183-196
CrossRef116
Nancy R. Cook. (2010) Assessing the Incremental Role of Novel and Emerging Risk Factors. Current Cardiovascular Risk Reports 4:2, 112-119
CrossRef117
Tamio Teramoto, Kazuyuki Shimada, Shinichiro Uchiyama, Masahiro Sugawara, Yoshio Goto, Nobuhiro Yamada, Shinichi Oikawa, Katsuyuki Ando, Naoki Ishizuka, Tsutomu Yamazaki, Kenji Yokoyama, Mitsuru Murata, Yasuo Ikeda. (2010) Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)—A randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. American Heart Journal 159:3, 361-369.e4
CrossRef118
I-Min Lee, Jennifer Lin, Amy J. Castonguay, Nathaniel S. Barton, Julie E. Buring, Robert Y.L. Zee. (2010) Mean leukocyte telomere length and risk of incident colorectal carcinoma in women: a prospective, nested case-control study. Clinical Chemistry and Laboratory Medicine 48:2, 259-262
CrossRef119
Chunyu Zhang, Aijun Sun, Peng Zhang, Chaoneng Wu, Shuning Zhang, Mingqiang Fu, Keqiang Wang, Yunzeng Zou, Junbo Ge. (2010) Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Research and Clinical Practice 87:2, 211-218
CrossRef120
Joseph E. Beshay, Howard Morgan, Christopher Madden, Wengui Yu, Ravindra Sarode. (2010) Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. Journal of Neurosurgery 112:2, 307-318
CrossRef121
Mori J Krantz, Jeffrey S Berger, William R Hiatt. (2010) An Aspirin a Day: Are We Barking Up the Wrong Willow Tree?. Pharmacotherapy 30:2, 115-118
CrossRef122
James E. Dalen. (2010) Aspirin for the Primary Prevention of Stroke and Myocardial Infarction: Ineffective or Wrong Dose?. The American Journal of Medicine 123:2, 101-102
CrossRef123
Luke Tapp, Eduard Shantsila, Gregory Y.H. Lip. (2010) Aspirin—A Drug Whose Time Has Gone?. The American Journal of Cardiology 105:4, 577-578
CrossRef124
Massimo Volpe, Diana Chin, Francesco Paneni. (2010) The challenge of polypharmacy in cardiovascular medicine. Fundamental & Clinical Pharmacology 24:1, 9-17
CrossRef125
Xunzhe Yang, Xiaoxi Zeng, Taixiang Wu, Taixiang Wu. 2010. Chuanxiong preparations for preventing stroke. .
CrossRef126
Xavier Borrás, Nekane Murga, Miquel Fiol, Milagros Pedreira. (2010) Novedades en cardiología clínica: electrocardiografía de superficie, enfermedad vascular y mujer y novedades terapéuticas. Revista Española de Cardiología 63, 3-16
CrossRef127
L Christine Turtzo, Louise D McCullough. (2010) Sex-specific responses to stroke. Future Neurology 5:1, 47-59
CrossRef128
Eli I. Lev, Alejandro Solodky, Naama Harel, Aviv Mager, David Brosh, Abid Assali, Milton Roller, Alexander Battler, Neal S. Kleiman, Ran Kornowski. (2010) Treatment of Aspirin-Resistant Patients With Omega-3 Fatty Acids Versus Aspirin Dose Escalation. Journal of the American College of Cardiology 55:2, 114-121
CrossRef129
Diana E. Ayala, Ramón C. Hermida. (2010) SEX DIFFERENCES IN THE ADMINISTRATION-TIME-DEPENDENT EFFECTS OF LOW-DOSE ASPIRIN ON AMBULATORY BLOOD PRESSURE IN HYPERTENSIVE SUBJECTS. Chronobiology International 27:2, 345-362
CrossRef130
Rebecca F. Gottesman, Argye E. Hillis. 2010. Gender Differences in Stroke. , 129-135.
CrossRef131
Shari S. Bassuk, JoAnn E. Manson. 2010. Gender-Specific Aspects of Selected Coronary Heart Disease Risk FactorsA Summary of the Epidemiologic Evidence. , 162-174.
CrossRef132
Lennart Welin, Lars Wilhelmsen, Arne Björnberg, Anders Odén. (2009) Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study. Pharmacoepidemiology and Drug Safety 18:12, 1143-1149
CrossRef133
F. Follath. (2009) Ethical considerations in cardiovascular prevention. Fundamental & Clinical Pharmacology 23:6, 669-673
CrossRef134
William G. Christen, Robert J. Glynn, Emily Y. Chew, Julie E. Buring. (2009) Low-Dose Aspirin and Medical Record–Confirmed Age-related Macular Degeneration in a Randomized Trial of Women. Ophthalmology 116:12, 2386-2392
CrossRef135
Magdalena Heras, Alfonso del Río. (2009) Update on Antiplatelet Therapy in Acute Coronary Syndromes. American Journal Cardiovascular Drugs 9:Supplement 1, 13-17
CrossRef136
Alex R. Hobson, Zeshan Qureshi, Phil Banks, Nick Curzen. (2009) Gender and Responses to Aspirin and Clopidogrel: Insights Using Short Thrombelastography. Cardiovascular Therapeutics 27:4, 246-252
CrossRef137
Marcela Manríquez, Antonio Vallano. (2009) Ácido acetilsalicílico y prevención primaria cardiovascular en ancianos. Revista Española de Geriatría y Gerontología 44:6, 349-351
CrossRef138
Nerses Sanossian, Bruce Ovbiagele. (2009) Prevention and management of stroke in very elderly patients. The Lancet Neurology 8:11, 1031-1041
CrossRef139
D.R. Jovanović, Lj. Beslać-Bumbaširević, M. Budimkić, T. Pekmezović, M. Živković, V.S. Kostić. (2009) Do women benefit more from systemic thrombolysis in acute ischemic stroke? A Serbian experience with thrombolysis in ischemic stroke (SETIS) study. Clinical Neurology and Neurosurgery 111:9, 729-732
CrossRef140
Jeffrey S. Berger, Deepak L. Bhatt, Christopher P. Cannon, Zhengming Chen, Lixin Jiang, James B. Jones, Shamir R. Mehta, Marc S. Sabatine, Steven R. Steinhubl, Eric J. Topol, Peter B. Berger. (2009) The Relative Efficacy and Safety of Clopidogrel in Women and Men. Journal of the American College of Cardiology 54:21, 1935-1945
CrossRef141
Catherine Kreatsoulas, Sonia Anand. (2009) Considering race/ethnicity and socio-economic status in randomized controlled trials. A commentary on Frampton et al.'s systematic review generalizing trial findings and tackling health disparities in asthma research. Social Science & Medicine 69:8, 1155-1156
CrossRef142
Stuart G. Baker, Nancy R. Cook, Andrew Vickers, Barnett S. Kramer. (2009) Using relative utility curves to evaluate risk prediction. Journal of the Royal Statistical Society: Series A (Statistics in Society) 172:4, 729-748
CrossRef143
Peter Malfertheiner, Francis KL Chan, Kenneth EL McColl. (2009) Peptic ulcer disease. The Lancet 374:9699, 1449-1461
CrossRef144
M Schürks, JE Buring, T Kurth. (2009) Agreement of self-reported migraine with ICHD-II criteria in the Women's Health Study. Cephalalgia 29:10, 1086-1090
CrossRef145
Domenico Praticò, Jean-Michel Dogné. (2009) Vascular biology of eicosanoids and atherogenesis. Expert Review of Cardiovascular Therapy 7:9, 1079-1089
CrossRef146
Molly B. Conroy, Jacob R. Sattelmair, Nancy R. Cook, JoAnn E. Manson, Julie E. Buring, I-Min Lee. (2009) Physical activity, adiposity, and risk of endometrial cancer. Cancer Causes & Control 20:7, 1107-1115
CrossRef147
M Schürks, RYL Zee, JE Buring, T Kurth. (2009) MTHFR 677C→T and ACE D/I polymorphisms and migraine attack frequency in women. Cephalalgia
CrossRef148
Ali Yazdanyar, Anne B. Newman. (2009) Evolving concepts of cardiovascular disease prevention in older adults. Current Cardiovascular Risk Reports 3:5, 366-373
CrossRef149
Sabine Oertelt-Prigione, Vera Regitz-Zagrosek. (2009) Gender Aspects in Cardiovascular Pharmacology. Journal of Cardiovascular Translational Research 2:3, 258-266
CrossRef150
Udaya S. Tantry, Elisabeth Mahla, Paul A. Gurbel. (2009) Aspirin Resistance. Progress in Cardiovascular Diseases 52:2, 141-152
CrossRef151
Jill S. Burkiewicz, Kathy E. Komperda. (2009) An Elective Course on Landmark Trials to Improve Pharmacy Students' Literature Evaluation and Therapeutic Application Skills. American Journal of Pharmaceutical Education 73:2, 31
CrossRef152
José A. Páramo. (2009) Diferencias de sexo y enfermedad arterial coronaria. Clínica e Investigación en Arteriosclerosis 21:4, 190-192
CrossRef153
A. Kautzky-Willer, A. Handisurya. (2009) Metabolic diseases and associated complications: sex and gender matter!. European Journal of Clinical Investigation 39:8, 631-648
CrossRef154
Thomas J. Kiernan, Bryan P. Yan, Michael R. Jaff. (2009) Antiplatelet therapy for the primary and secondary prevention of cerebrovascular events in patients with extracranial carotid artery disease. Journal of Vascular Surgery 50:2, 431-439
CrossRef155
Alessandra C. Goulart, Kathryn M. Rexrode, Suzanne Cheng, Lynda Rose, Julie E. Buring, Paul M. Ridker, Robert Y.L. Zee. (2009) Association of genetic variants with the metabolic syndrome in 20,806 white women: The women's health genome study. American Heart Journal 158:2, 257-262.e1
CrossRef156
Joshua A. Beckman. (2009) Antithrombotic therapies in cerebrovascular disease: What should we use as secondary prevention in patients with carotid artery disease?. Catheterization and Cardiovascular Interventions 74:S1, S12-S16
CrossRef157
Paul Muntner, Suma Vupputuri, Josef Coresh, Jaime Uribarri, Caroline S Fox. (2009) Metabolic abnormalities are present in adults with elevated serum cystatin C. Kidney International 76:1, 81-88
CrossRef158
Markus Schürks, Tobias Kurth, Julie E. Buring, Robert Y.L. Zee. (2009) A Candidate Gene Association Study of 77 Polymorphisms in Migraine. The Journal of Pain 10:7, 759-766
CrossRef159
Paul M. Ridker. (2009) Moving toward new statin guidelines in a post-JUPITER world: Principles to consider. Current Atherosclerosis Reports 11:4, 249-256
CrossRef160
Lisa Swaim, Robert S. Hillman. (2009) Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women’s health study. Journal of Thrombosis and Thrombolysis 28:1, 94-100
CrossRef161
Alessandra C. Goulart, Robert Y.L. Zee, Kathryn M. Rexrode. (2009) Estrogen receptor 1 gene polymorphisms and decreased risk of obesity in women. Metabolism 58:6, 759-764
CrossRef162
D. Conen, R. J. Glynn, P. M. Ridker, J. E. Buring, M. A. Albert. (2009) Socioeconomic status, blood pressure progression, and incident hypertension in a prospective cohort of female health professionals. European Heart Journal 30:11, 1378-1384
CrossRef163
G. Telman, E. Kouperberg, E. Sprecher, D. Yarnitsky. (2009) Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients. Journal of the Neurological Sciences 281:1-2, 2-5
CrossRef164
G. Jackson. (2009) Aspirin: not currently for primary prevention in diabetes. International Journal of Clinical Practice 63:6, 831-832
CrossRef165
S. Shakib. (2009) Aspirin for primary prevention: do potential benefits outweigh the risks?. Internal Medicine Journal 39:6, 401-407
CrossRef166
Dara G. Jamieson, Maryna Skliut. (2009) Gender Considerations in Stroke Management. The Neurologist 15:3, 132-141
CrossRef167
Claudio Napoli, Francesco Cacciatore. (2009) Novel Pathogenic Insights in the Primary Prevention of Cardiovascular Disease. Progress in Cardiovascular Diseases 51:6, 503-523
CrossRef168
Nina P. Paynter, Nancy R. Cook, Brendan M. Everett, Howard D. Sesso, Julie E. Buring, Paul M. Ridker. (2009) Prediction of Incident Hypertension Risk in Women with Currently Normal Blood Pressure. The American Journal of Medicine 122:5, 464-471
CrossRef169
James E. Dalen. (2009) Aspirin for Prevention of Myocardial Infarction and Stroke. Journal of the American College of Cardiology 53:21, 2010
CrossRef170
A. Siddique, M. Butt, E. Shantsila, G. Y. H. Lip. (2009) New antiplatelet drugs: beyond aspirin and clopidogrel. International Journal of Clinical Practice 63:5, 776-789
CrossRef171
C. Hendricks Brown, Thomas R. Ten Have, Booil Jo, Getachew Dagne, Peter A. Wyman, Bengt Muthén, Robert D. Gibbons. (2009) Adaptive Designs for Randomized Trials in Public Health. Annual Review of Public Health 30:1, 1-25
CrossRef172
Michelle A. Albert, Guillaume Pare, Alanna Morris, Lynda Rose, Julie Buring, Paul M. Ridker, Robert Y.L. Zee. (2009) Candidate genetic variants in the fibrinogen, methylenetetrahydrofolate reductase, and intercellular adhesion molecule-1 genes and plasma levels of fibrinogen, homocysteine, and intercellular adhesion molecule-1 among various race/ethnic groups: Data from the Women's Genome Health Study. American Heart Journal 157:4, 777-783.e1
CrossRef173
&NA;. (2009) Sex-Related Differences in Outcome After High-Risk Vascular Surgery After the Administration of β-Adrenergic-Blocking Drugs. Survey of Anesthesiology 53:2, 78-79
CrossRef174
Jun Li, Louise D McCullough. (2009) Sex differences in minocycline-induced neuroprotection after experimental stroke. Journal of Cerebral Blood Flow & Metabolism 29:4, 670-674
CrossRef175
Alessandra C. Goulart, Robert Y.L. Zee, Aruna Pradhan, Kathryn M. Rexrode. (2009) Associations of the Estrogen Receptors 1 and 2 Gene Polymorphisms With the Metabolic Syndrome in Women. Metabolic Syndrome and Related Disorders 7:2, 111-117
CrossRef176
Daniel I. Chasman, Dov Shiffman, Robert Y.L. Zee, Judy Z. Louie, May M. Luke, Charles M. Rowland, Joseph J. Catanese, Julie E. Buring, James J. Devlin, Paul M. Ridker. (2009) Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 203:2, 371-376
CrossRef177
C. Kriatselis. (2009) Alkoholkonsum und Risiko für das Auftreten von Vorhofflimmern bei Frauen. Der Kardiologe 3:2, 134-136
CrossRef178
Michael Gardner, John Palmer, Camila Manrique, Guido Lastra, David W. Gardner, James R. Sowers. (2009) Utility of Aspirin Therapy in Patients With the Cardiometabolic Syndrome and Diabetes. Journal of the CardioMetabolic Syndrome 4:2, 96-101
CrossRef179
David Conen, Suzanne Cheng, Lori L Steiner, Julie E Buring, Paul M Ridker, Robert YL Zee. (2009) Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Womenʼs Genome Health Study. Journal of Hypertension 27:3, 476-483
CrossRef180
L. Björklund, M.-A. Wallander, S. Johansson, E. Lesén. (2009) Aspirin in cardiology - benefits and risks. International Journal of Clinical Practice 63:3, 468-477
CrossRef181
Elizabeth W. Karlson, Lori B. Chibnik, Shelley S. Tworoger, I-Min Lee, Julie E. Buring, Nancy A. Shadick, JoAnn E. Manson, Karen H. Costenbader. (2009) Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis & Rheumatism 60:3, 641-652
CrossRef182
Schlosser, Rodney J., . (2009) Epistaxis. New England Journal of Medicine 360:8, 784-789
Full Text183
Markus Schürks, Robert Y. L. Zee, Julie E. Buring, Tobias Kurth. (2009) Polymorphisms in the Renin-Angiotensin System and Migraine in Women. Headache: The Journal of Head and Face Pain 49:2, 292-299
CrossRef184
AC Winter, K Berger, JE Buring, T Kurth. (2009) Body mass index, migraine, migraine frequency and migraine features in women. Cephalalgia 29:2, 269-278
CrossRef185
Markus Schürks, Tobias Kurth, Paul M Ridker, Julie E. Buring, Robert Y.L. Zee. (2009) Association Between Polymorphisms in the β2-adrenoceptor Gene and Migraine in Women. Headache: The Journal of Head and Face Pain 49:2, 235-244
CrossRef186
Tamra E. Meyer, Dov Shiffman, Alanna C. Morrison, Charles M. Rowland, Judy Z. Louie, Lance A. Bare, David A. Ross, Andre R. Arellano, Daniel I. Chasman, Paul M. Ridker, James S. Pankow, Josef Coresh, Mary J. Malloy, John P. Kane, Stephen G. Ellis, James J. Devlin, Eric Boerwinkle. (2009) GOSR2 Lys67Arg Is Associated With Hypertension in Whites. American Journal of Hypertension 22:2, 163-168
CrossRef187
Francesca Santilli, Bianca Rocca, Raimondo De Cristofaro, Stefano Lattanzio, Laura Pietrangelo, Aida Habib, Caterina Pettinella, Antonio Recchiuti, Elisabetta Ferrante, Giovanni Ciabattoni, Giovanni Davì, Carlo Patrono. (2009) Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Journal of the American College of Cardiology 53:8, 667-677
CrossRef188
A.C. Goulart, R.Y.L. Zee, K.M. Rexrode. (2009) Association of estrogen receptor 2 gene polymorphisms with obesity in women (obesity and estrogen receptor 2 gene). Maturitas 62:2, 179-183
CrossRef189
Frank Bretz, Willi Maurer, Paul Gallo. (2009) Discussion of “Some Controversial Multiple Testing Problems in Regulatory Applications” by H. M. J. Hung and S.-J. Wang. Journal of Biopharmaceutical Statistics 19:1, 25-34
CrossRef190
Shinichiro Uchiyama. (2009) Primary stroke prevention by antithrombotic therapy. Nosotchu 31:6, 575-579
CrossRef191
Takashi Kawai, Tetsuya Yamagishi, Shinya Goto Shinya Goto. (2009) Circadian Variations of Gastrointestinal Mucosal Damage Detected with Transnasal Endoscopy in Apparently Healthy Subjects Treated with Low-Dose Aspirin (ASA) for a Short Period -Prevention Trial, Randomized Double-Blind Placebo Controlled Preliminary Trial. Journal of Atherosclerosis and Thrombosis 16:3, 155-163
CrossRef192
Kassem Barada, Heitham Abdul-Baki, Ihab I. El Hajj, Jana G. Hashash, Peter H. Green. (2009) Gastrointestinal Bleeding in the Setting of Anticoagulation and Antiplatelet Therapy. Journal of Clinical Gastroenterology 43:1, 5-12
CrossRef193
Young Sang Kim, Kyoung Kon Kim, In Cheol Hwang. (2009) Aspirin Usage Based on Evidence for the Prevention of Cardio-Cerebrovascular Disease. Korean Journal of Family Medicine 30:4, 249
CrossRef194
Brendan M. Everett, Sandeep Bansal, Nader Rifai, Julie E. Buring, Paul M. Ridker. (2009) Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis 202:1, 282-288
CrossRef195
Faisal A. Arain, Fatima H. Kuniyoshi, Ahmed D. Abdalrhim, Virginia M. Miller. (2009) Sex/Gender Medicine. Circulation Journal 73:10, 1774-1782
CrossRef196
J. Lin, N. R. Cook, C. Albert, E. Zaharris, J. M. Gaziano, M. Van Denburgh, J. E. Buring, J. E. Manson. (2008) Vitamins C and E and Beta Carotene Supplementation and Cancer Risk: A Randomized Controlled Trial. JNCI Journal of the National Cancer Institute 101:1, 14-23
CrossRef197
H. Benamer, B. Chevalier, M.-C. Morice. (2008) L’angioplastie coronaire chez la femme. Annales de Cardiologie et d'Angéiologie 57:6, 371-375
CrossRef198
Elizabeth W. Karlson, Nancy A. Shadick, Nancy R. Cook, Julie E. Buring, I.-min Lee. (2008) Vitamin E in the primary prevention of rheumatoid arthritis: The women's health study. Arthritis & Rheumatism 59:11, 1589-1595
CrossRef199
(2008) Estrogen and progestogen therapy in postmenopausal women. Fertility and Sterility 90:5, S88-S102
CrossRef200
Domenico Praticò. (2008) Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis 201:1, 8-16
CrossRef201
R. Charles Callison, Harold P. Adams. (2008) Use of Antiplatelet Agents for Prevention of Ischemic Stroke. Neurologic Clinics 26:4, 1047-1077
CrossRef202
Jeffrey S. Berger, C. Noel Bairey-Merz, Rita F. Redberg, Pamela S. Douglas. (2008) Improving the quality of care for women with cardiovascular disease. American Heart Journal 156:5, 816-825.e1
CrossRef203
M. Zimarino, R. De Caterina. (2008) Long-term treatment strategies for atherothrombotic disease: do platelets define the course?. European Heart Journal Supplements 10:Suppl I, I8-I13
CrossRef204
Tatjana Rundek, Ralph L. Sacco. (2008) Risk Factor Management to Prevent First Stroke. Neurologic Clinics 26:4, 1007-1045
CrossRef205
V. Regitz-Zagrosek, C. Schubert. (2008) Geschlechterunterschiede in der kardiovaskulären Pharmakotherapie. Der Internist 49:11, 1383-1390
CrossRef206
Cheryl D. Bushnell. (2008) Stroke in Women: Risk and Prevention Throughout the Lifespan. Neurologic Clinics 26:4, 1161-1176
CrossRef207
Wendy Rogers, Angela Ballantyne. (2008) When is sex-specific research appropriate?. International Journal of Feminist Approaches to Bioethics 1:2, 36-57
CrossRef208
Jodi R Godfrey, JoAnn E. Manson. (2008) Toward Optimal Health: Strategies for Prevention of Heart Disease in Women. Journal of Women's Health 17:8, 1271-1276
CrossRef209
P.D. Schellinger, P. Ringleb, W. Hacke. (2008) Leitlinien zum Management von Patienten mit akutem Hirninfarkt oder TIA der Europäischen Schlaganfallorganisation 2008. Der Nervenarzt 79:10, 1180-1202
CrossRef210
J. Michael Gaziano, Charles H. Hennekens. 2008. Physicians' Health Study (PHS). .
CrossRef211
David Conen, Robert J Glynn, Julie E Buring, Paul M Ridker, Robert YL Zee. (2008) Association of renin–angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort study. Journal of Hypertension 26:9, 1780-1786
CrossRef212
Niels Engberding, Nanette K Wenger. (2008) Cardiovascular disease prevention tailored for women. Expert Review of Cardiovascular Therapy 6:8, 1123-1134
CrossRef213
Rekha Mankad, Patricia JM Best. (2008) Cardiovascular disease in older women: a challenge in diagnosis and treatment. Women's Health 4:5, 449-464
CrossRef214
Howard N. Hodis, Wendy J. Mack. (2008) Postmenopausal Hormone Therapy and Cardiovascular Disease in Perspective. Clinical Obstetrics and Gynecology 51:3, 564-580
CrossRef215
José Biller. (2008) The role of antiplatelet therapy in the management of ischemic stroke: implementation of guidelines in current practice. Neurological Research 30:7, 669-677
CrossRef216
Rebecca P. Gelber, J. Michael Gaziano, E. John Orav, JoAnn E. Manson, Julie E. Buring, Tobias Kurth. (2008) Measures of Obesity and Cardiovascular Risk Among Men and Women. Journal of the American College of Cardiology 52:8, 605-615
CrossRef217
Cheryl Bushnell. (2008) Stroke prevention in women: Challenges and opportunities. Current Atherosclerosis Reports 10:4, 347-353
CrossRef218
Sheldon E. Litwin. (2008) Which Measures of Obesity Best Predict Cardiovascular Risk?. Journal of the American College of Cardiology 52:8, 616-619
CrossRef219
Esther S.H. Kim, Thomas P. Carrigan, Venu Menon. (2008) Enrollment of Women in National Heart, Lung, and Blood Institute-Funded Cardiovascular Randomized Controlled Trials Fails to Meet Current Federal Mandates for Inclusion. Journal of the American College of Cardiology 52:8, 672-673
CrossRef220
Anita Airee, Heather M Draper, Shannon W Finks. (2008) Aspirin Resistance: Disparities and Clinical Implications. Pharmacotherapy 28:8, 999-1018
CrossRef221
Jill R. Quinn. (2008) Women and heart disease. Nursing Management (Springhouse) 39:8, 22-27
CrossRef222
M. M. C. Hovens, J. D. Snoep, Y. Groeneveld, M. Frlich, J. T. Tamsma, M. V. Huisman. (2008) Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. Diabetes, Obesity and Metabolism 10:8, 668-674
CrossRef223
Goran Bjelakovic, Dimitrinka Nikolova, Rosa G Simonetti, Christian Gluud, Goran Bjelakovic. 2008. Antioxidant supplements for preventing gastrointestinal cancers. .
CrossRef224
Jacqueline Suk Danik, Nader Rifai, Julie E. Buring, Paul M. Ridker. (2008) Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events. Journal of the American College of Cardiology 52:2, 124-131
CrossRef225
Robina Matyal. (2008) Newly Appreciated Pathophysiology of Ischemic Heart Disease in Women Mandates Changes in Perioperative Management: A Core Review. Anesthesia & Analgesia 107:1, 37-50
CrossRef226
Marcin Dobaczewski, Marek Nocun, Ilya Zavodnik, Olga Ulicna, Elena Lapshina, Leu Zavodnik, Jacek Golanski, Piotr Kazmierczak, Zdenka Durackova, Barbara Kostka, Leszek Markuszewski, Cezary Watala. (2008) Targeting the urine and plasma determinants of thromboxane A2 metabolism in detection of aspirin effectiveness. Blood Coagulation & Fibrinolysis 19:5, 421-428
CrossRef227
I-MIN LEE, DAVID M. BUCHNER. (2008) The Importance of Walking to Public Health. Medicine & Science in Sports & Exercise 40:Supplement, S512-S518
CrossRef228
Shannon W. Finks. (2008) Re-examining the Cardiovascular Therapeutic Benefits of Aspirin. Southern Medical Journal 101:7, 679-680
CrossRef229
Robina Matyal, Feroze Mahmood, Peter Panzica, Frank Pomposelli, Kyung W. Park, Allen Hamden, Mark Schermerhorn, Philip Hess. (2008) Sex-Related Differences in Outcome After High-Risk Vascular Surgery After the Administration of β-Adrenergic–Blocking Drugs. Journal of Cardiothoracic and Vascular Anesthesia 22:3, 354-360
CrossRef230
Guan-Ying Tseng, Hwai-Jeng Lin. (2008) Aspirin Prescription and Outcomes in Hemodialysis Patients. American Journal of Kidney Diseases 51:6, 1070-1071
CrossRef231
Fatma Ferda Verit, Ozcan Erel, Hakim Celik. (2008) Paraoxonase-1 activity in patients with hyperemesis gravidarum. Redox Report 13:3, 134-138
CrossRef232
Olivia I. Okereke, Jae H. Kang, Nancy R. Cook, J. Michael Gaziano, JoAnn E. Manson, Julie E. Buring, Francine Grodstein. (2008) Type 2 Diabetes Mellitus and Cognitive Decline in Two Large Cohorts of Community-Dwelling Older Adults. Journal of the American Geriatrics Society 56:6, 1028-1036
CrossRef233
Szalat Auryan, Raz Itamar. (2008) Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes, Obesity and Metabolism 0:0, 080520205432340-???
CrossRef234
Geoffrey A Donnan, Marc Fisher, Malcolm Macleod, Stephen M Davis. (2008) Stroke. The Lancet 371:9624, 1612-1623
CrossRef235
Rehan Qayyum, Diane M. Becker, Lisa R. Yanek, Taryn F. Moy, Lewis C. Becker, Nauder Faraday, Dhananjay Vaidya. (2008) Platelet Inhibition by Aspirin 81 and 325 mg/day in Men Versus Women Without Clinically Apparent Cardiovascular Disease. The American Journal of Cardiology 101:9, 1359-1363
CrossRef236
William G. Christen, Robert J. Glynn, Emily Y. Chew, Julie E. Buring. (2008) Vitamin E and Age-Related Cataract in a Randomized Trial of Women. Ophthalmology 115:5, 822-829.e1
CrossRef237
Dimitris P Papadopoulos, Vasilios Papademetriou. (2008) Aggressive blood pressure control and stroke prevention: role of calcium channel blockers. Journal of Hypertension 26:5, 844-852
CrossRef238
Lina Badimon, Gemma Vilahur. (2008) Enfermedad aterotrombótica coronaria: avances en el tratamiento antiplaquetario. Revista Española de Cardiología 61:5, 501-513
CrossRef239
Armen Yuri Gasparyan, Timothy Watson, Gregory Y.H. Lip. (2008) The Role of Aspirin in Cardiovascular Prevention. Journal of the American College of Cardiology 51:19, 1829-1843
CrossRef240
Wendy A. Rogers, Angela J. Ballantyne. (2008) Exclusion of Women From Clinical Research: Myth or Reality?. Mayo Clinic Proceedings 83:5, 536-542
CrossRef241
W. A. Rogers, A. J. Ballantyne, . (2008) Exclusion of Women From Clinical Research: Myth or Reality?. Mayo Clinic Proceedings 83:5, 536-542
CrossRef242
D. Conen, R. J. Glynn, J. E. Buring, P. M Ridker, R. Y. Zee. (2008) Renin–angiotensin and endothelial nitric oxide synthase gene polymorphisms are not associated with the risk of incident type 2 diabetes mellitus: a prospective cohort study. Journal of Internal Medicine 263:4, 376-385
CrossRef243
Nadir Arber, Bernard Levin. (2008) Chemoprevention of Colorectal Neoplasia: The Potential for Personalized Medicine. Gastroenterology 134:4, 1224-1237
CrossRef244
A. Z. LaCroix, S. L. Gray, A. Aragaki, B. B. Cochrane, A. B. Newman, C. L. Kooperberg, H. Black, J. D. Curb, P. Greenland, N. F. Woods. (2008) Statin Use and Incident Frailty in Women Aged 65 Years or Older: Prospective Findings From the Women's Health Initiative Observational Study. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 63:4, 369-375
CrossRef245
Nanette K. Wenger. (2008) Preventing Cardiovascular Disease in Women: An Update. Clinical Cardiology 31:3, 109-113
CrossRef246
Emily B. Levitan, Nancy R. Cook, Meir J. Stampfer, Paul M. Ridker, Kathryn M. Rexrode, Julie E. Buring, JoAnn E. Manson, Simin Liu. (2008) Dietary glycemic index, dietary glycemic load, blood lipids, and C-reactive protein. Metabolism 57:3, 437-443
CrossRef247
Katia Rivero, Vera Lúcia Portal, Matias Vieira, Ivo Behle. (2008) Prevalence of the impaired glucose metabolism and its association with risk factors for coronary artery disease in women with gestational diabetes. Diabetes Research and Clinical Practice 79:3, 433-437
CrossRef248
Yoshihiro Fukumoto, Satoshi Yasuda, Akira Ito, Hiroaki Shimokawa. (2008) Prognostic Effects of Benidipine in Patients With Vasospastic Angina: Comparison With Diltiazem and Amlodipine. Journal of Cardiovascular Pharmacology 51:3, 253-257
CrossRef249
Samer Ellahham. (2008) Role of Antiplatelet Agents in the Primary and Secondary Prevention of Atherothrombotic Events in High Risk-Patients. Southern Medical Journal 101:3, 273-283
CrossRef250
Geoffrey S. F. Ling. (2008) Aggressive management of ischemic stroke: The case for the hospitalist. Journal of Hospital Medicine 3:S2, S9-S14
CrossRef251
Michelle A. Albert, Robert J. Glynn, Julie E. Buring, Paul M. Ridker. (2008) Differential effect of soluble intercellular adhesion molecule-1 on the progression of atherosclerosis as compared to arterial thrombosis: A prospective analysis of the Women's Health Study. Atherosclerosis 197:1, 297-302
CrossRef252
Julie E. Buring. (2008) Primary Data Collection. Epidemiology 19:2, 347-349
CrossRef253
Mark J. Alberts. (2008) CHARISMA revisited: is the glass half full or just empty?. International Journal of Stroke 3:1, 16-19
CrossRef254
E. B. Levitan, S. Liu, M. J. Stampfer, N. R. Cook, K. M. Rexrode, P. M. Ridker, J. E. Buring, J. E. Manson. (2008) HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia 51:2, 267-275
CrossRef255
M. Cattaneo. (2008) Haemorrhagic stroke during anti-platelet therapy. European Journal of Anaesthesiology 25:Supplement 42, 12-15
CrossRef256
Nancy R. Cook. (2008) Comments on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond’ by M. J. Pencinaet al.,Statistics in Medicine (DOI: 10.1002/sim.2929). Statistics in Medicine 27:2, 191-195
CrossRef257
Giulio Illuminati, Jean-Baptiste Ricco, Francesco G. Caliò, Antonio D’Urso, Gianluca Ceccanei, Francesco Vietri. (2008) Results in a consecutive series of 83 surgical corrections of symptomatic stenotic kinking of the internal carotid artery. Surgery 143:1, 134-139
CrossRef258
Goran Bjelakovic, Lise Lotte Gluud, Dimitrinka Nikolova, Kate Whitfield, Jørn Wetterslev, Christian Gluud, Goran Bjelakovic. 2008. .
CrossRef259
G. Bolte. (2008) Gender in der Epidemiologie. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 51:1, 3-12
CrossRef260
(2008) Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. Revista Española de Cardiología 61:1, 82.e1-82.e49
CrossRef261
Bertram L. Kasiske, Ajay K. Israni. 2008. Cardiovascular Complications after Renal Transplantation. , 469-491.
CrossRef262
Marcus Shaker, Ano Lobb, Pamela Jenkins, Daniel O'Rourke, Steve K. Takemoto, Salil Sheth, Thomas Burroughs, Mark S. Dykewicz. (2008) An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology 121:1, 81-87
CrossRef263
Dov Shiffman, Daniel I. Chasman, Robert Y.L. Zee, Olga A. Iakoubova, Judy Z. Louie, James J. Devlin, Paul M. Ridker. (2008) A Kinesin Family Member 6 Variant Is Associated With Coronary Heart Disease in the Women’s Health Study. Journal of the American College of Cardiology 51:4, 444-448
CrossRef264
Michael W. Tempelhof, L Kristin Newby. (2008) Platelet Inhibitors. Cardiology in Review 16:1, 23-29
CrossRef265
N K Wenger, L J Shaw, V Vaccarino. (2008) Coronary Heart Disease in Women: Update 2008. Clinical Pharmacology & Therapeutics 83:1, 37-51
CrossRef266
Cindy Grines, Leslie Cho. (2008) Atherothrombotic Disease and the Role of Antiplatelet Therapy in Women. Journal of Women's Health 17:1, 35-46
CrossRef267
(2008) Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovascular Diseases 25:5, 457-507
CrossRef268
Charles H Hennekens, Wendy R Schneider. (2008) The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Review of Cardiovascular Therapy 6:1, 95-107
CrossRef269
Yiqing Song, JoAnn E. Manson, James B. Meigs, Paul M. Ridker, Julie E. Buring, Simin Liu. (2007) Comparison of Usefulness of Body Mass Index Versus Metabolic Risk Factors in Predicting 10-Year Risk of Cardiovascular Events in Women. The American Journal of Cardiology 100:11, 1654-1658
CrossRef270
(2007) The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. European Journal of Epidemiology 22:12, 839-869
CrossRef271
Alipio Mangas Rojas, Francisco Gómez Rodríguez. (2007) Tratamiento multifactorial de la arteriosclerosis. Medicina Clínica 129:20, 785-796
CrossRef272
Bhatt, Deepak L., . (2007) Intensifying Platelet Inhibition — Navigating between Scylla and Charybdis. New England Journal of Medicine 357:20, 2078-2081
Full Text273
T Kurth, PM Ridker, JE Buring. (2007) Migraine and biomarkers of cardiovascular disease in women. Cephalalgia 0:0, 071106213020003-???
CrossRef274
Colin D Funk, Garret A FitzGerald. (2007) COX-2 Inhibitors and Cardiovascular Risk. Journal of Cardiovascular Pharmacology 50:5, 470-479
CrossRef275
Lori A. Blauwet, Rita F. Redberg. (2007) The Role of Sex-Specific Results Reporting in Cardiovascular Disease. Cardiology in Review 15:6, 275-278
CrossRef276
Amandev K. Aulakh, Sonia S. Anand. (2007) Sex and Gender Subgroup Analyses of Randomized Trials. Women's Health Issues 17:6, 342-350
CrossRef277
Charles H. Hennekens. (2007) Aspirin in the treatment and prevention of cardiovascular disease: Current perspectives and future directions. Current Atherosclerosis Reports 9:5, 409-416
CrossRef278
Thomas S. Bowman, J. Michael Gaziano, Julie E. Buring, Howard D. Sesso. (2007) A Prospective Study of Cigarette Smoking and Risk of Incident Hypertension in Women. Journal of the American College of Cardiology 50:21, 2085-2092
CrossRef279
Auryan Szalat, Itamar Raz. (2007) Gender-specific care of diabetes. Women's Health 3:6, 735-764
CrossRef280
W F Coutinho. (2007) The obese older female patient: CV risk and the SCOUT study. International Journal of Obesity 31, S26-S30
CrossRef281
AMR Billeci, V Caso, M Paciaroni, F Palmerini, G Agnelli. (2007) Hormone-replacement therapy, dementia and stroke. Women's Health 3:6, 699-710
CrossRef282
Taixiang Wu, Xunzhe Yang, Xiaoxi Zeng, Taixiang Wu. 2007. Chuanxiong type compounds for preventing cardiovascular diseases. .
CrossRef283
M. J. Alberts, B. Ovbiagele. (2007) Current strategies for ischemic stroke prevention: role of multimodal combination therapies. Journal of Neurology 254:10, 1414-1426
CrossRef284
Margaret May, Debbie A. Lawlor, Rita Patel, Ann Rumley, Gordon Lowe, Shah Ebrahim. (2007) Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Womenʼs Heart and Health cohort study. European Journal of Cardiovascular Prevention & Rehabilitation 14:5, 638-645
CrossRef285
David Atkins. (2007) Creating and Synthesizing Evidence With Decision Makers in Mind. Medical Care 45:Suppl 2, S16-S22
CrossRef286
Kaleb Michaud, Frederick Wolfe. (2007) Comorbidities in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 21:5, 885-906
CrossRef287
&NA;. (2007) FULL TEXT Chapter 1: Introduction. European Journal of Cardiovascular Prevention & Rehabilitation 14:Supplement 2, S2-S113
CrossRef288
Ian Graham. (2007) European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis 194:1, 1-45
CrossRef289
Judith Hsia. (2007) PRO: Should Aspirin Be Used in All Women Older Than 65 Years to Prevent Stroke?. Preventive Cardiology 10:s4, 6-11
CrossRef290
Howard N. Hodis, Wendy J. Mack. (2007) Postmenopausal hormone therapy in clinical perspective. Menopause 14:5, 944-957
CrossRef291
Julie E. Buring. (2007) CON: Should Aspirin Be Used in All Women Older Than 65 Years to Prevent Stroke?. Preventive Cardiology 10:s4, 12-18
CrossRef292
Lori Mosca. (2007) Does an Aspirin a Day Really Keep a Stroke Away?. Preventive Cardiology 10:s4, 26-27
CrossRef293
(2007) Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007. Revista Española de Cardiología 60:9, 968.e1-968.e94
CrossRef294
Yu Chen, Gwendolyn E. Kuehl, Jeannette Bigler, Christine F. Rimorin, Yvonne Schwarz, Danny D. Shen, Johanna W. Lampe. (2007) UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. Pharmacogenetics and Genomics 17:8, 571-579
CrossRef295
Erhard Haus. (2007) Chronobiology of hemostasis and inferences for the chronotherapy of coagulation disorders and thrombosis prevention. Advanced Drug Delivery Reviews 59:9-10, 966-984
CrossRef296
Aruna D. Pradhan, Nader Rifai, Julie E. Buring, Paul M. Ridker. (2007) Hemoglobin A1c Predicts Diabetes but Not Cardiovascular Disease in Nondiabetic Women. The American Journal of Medicine 120:8, 720-727
CrossRef297
Justin R Hamilton, Zane Kaplan, Shaun P Jackson, Stephen Opat. (2007) Antiplatelet therapy: present status and future prospects. Expert Opinion on Drug Discovery 2:8, 1035-1040
CrossRef298
Julinda Mehilli, Gjin Ndrepepa, Adnan Kastrati, Franz-Josef Neumann, Jurriën ten Berg, Olga Bruskina, Franz Dotzer, Melchior Seyfarth, Jürgen Pache, Sebastian Kufner, Josef Dirschinger, Peter B. Berger, Albert Schömig. (2007) Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: Results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. American Heart Journal 154:1, 158.e1-158.e7
CrossRef299
Nanette K Wenger. (2007) The Reynolds Risk Score: improved accuracy for cardiovascular risk prediction in women?. Nature Clinical Practice Cardiovascular Medicine 4:7, 366-367
CrossRef300
Doruk Erkan, Melanie J. Harrison, Roger Levy, Margaret Peterson, Michelle Petri, Lisa Sammaritano, Aynur Unalp-Arida, Veronica Vilela, Yusuf Yazici, Michael D. Lockshin. (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody–positive individuals. Arthritis & Rheumatism 56:7, 2382-2391
CrossRef301
M. M. C. HOVENS, J. D. SNOEP, Y. GROENEVELD, J. T. TAMSMA, J. C. J. EIKENBOOM, M. V. HUISMAN. (2007) High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes. Journal of Thrombosis and Haemostasis 5:7, 1562-1564
CrossRef302
S. M. Zhang, J. Lin, N. R. Cook, I-M. Lee, J. E. Manson, J. E. Buring, P. M. Ridker. (2007) C-Reactive Protein and Risk of Breast Cancer. JNCI Journal of the National Cancer Institute 99:11, 890-894
CrossRef303
A. Bardia, J. O. Ebbert, R. A. Vierkant, P. J. Limburg, K. Anderson, A. H. Wang, J. E. Olson, C. M. Vachon, J. R. Cerhan. (2007) Association of Aspirin and Nonaspirin Nonsteroidal Anti-inflammatory Drugs With Cancer Incidence and Mortality. JNCI Journal of the National Cancer Institute 99:11, 881-889
CrossRef304
Hans-Christoph Diener, Tobias Kurth, David Dodick. (2007) Patent foramen ovale, stroke, and cardiovascular disease in migraine. Current Opinion in Neurology 20:3, 310-319
CrossRef305
Sandeep Bansal, Paul M. Ridker. (2007) Comparison of Characteristics of Future Myocardial Infarctions in Women With Baseline High Versus Baseline Low Levels of High-Sensitivity C-Reactive Protein. The American Journal of Cardiology 99:11, 1500-1503
CrossRef306
Nanette K. Wenger. (2007) Clinical guidelines for cardiovascular disease prevention: Should they differ by gender?. Current Cardiovascular Risk Reports 1:2, 148-152
CrossRef307
Elio Agostoni, Angelo Aliprandi. (2007) Migraine and cardiocerebrovascular risk in women. Women's Health 3:3, 369-379
CrossRef308
Michelle A. Albert, Robert J. Glynn, Julie E. Buring, Paul M. Ridker. (2007) Relation Between Soluble Intercellular Adhesion Molecule-1, Homocysteine, and Fibrinogen Levels and Race/Ethnicity in Women Without Cardiovascular Disease. The American Journal of Cardiology 99:9, 1246-1251
CrossRef309
Peng-yun A. Huang, Julie E. Buring, Paul M. Ridker, Robert J. Glynn. (2007) Awareness, Accuracy, and Predictive Validity of Self-Reported Cholesterol in Women. Journal of General Internal Medicine 22:5, 606-613
CrossRef310
Cheryl D Bushnell. (2007) Endogenous sex steroids and ischemic stroke risk in older women. Aging Health 3:2, 201-207
CrossRef311
Joseph E Thomas, JoAnne Micale Foody. (2007) Aspirin for primary prevention of cardiovascular disease in older persons: where is the evidence?. Aging Health 3:2, 159-164
CrossRef312
Biljana Miljanović, Reza Dana, David A. Sullivan, Debra A. Schaumberg. (2007) Impact of Dry Eye Syndrome on Vision-Related Quality of Life. American Journal of Ophthalmology 143:3, 409-415.e2
CrossRef313
H. M. Cheng, Z. X. Ye, K. R. Chiou, S. J. Lin, M. J. Charng. (2007) Vascular stiffness in familial hypercholesterolaemia is associated with C-reactive protein and cholesterol burden. European Journal of Clinical Investigation 37:3, 197-206
CrossRef314
Carmen Maciá Bobes, Aránzazu Ronzón Fernández, Elisa Fernández García. (2007) La prevención primaria con aspirina de enfermedades cardiovasculares en pacientes diabéticos. ¿Qué pruebas sustentan los criterios de la ADA?. Atención Primaria 39:3, 163-164
CrossRef315
Javier Sanz, Pedro R Moreno, Valentin Fuster. (2007) Update on advances in atherothrombosis. Nature Clinical Practice Cardiovascular Medicine 4:2, 78-89
CrossRef316
Patrick M. Lynch. (2007) The role of aspirin in the prevention of polyp recurrence: What is the right dose?. Current Colorectal Cancer Reports 3:1, 24-28
CrossRef317
Terry Ann Chambers, Aisha Bagai, Natalia Ivascu. (2007) Current trends in coronary artery disease in women. Current Opinion in Anaesthesiology 20:1, 75-82
CrossRef318
Lori A. Blauwet, Sharonne N. Hayes, David McManus, Rita F. Redberg, Mary Norine Walsh. (2007) Low Rate of Sex-Specific Result Reporting in Cardiovascular Trials. Mayo Clinic Proceedings 82:2, 166-170
CrossRef319
L. A. Blauwet, S. N. Hayes, D. McManus, R. F. Redberg, M. N. Walsh. (2007) Low Rate of Sex-Specific Result Reporting in Cardiovascular Trials. Mayo Clinic Proceedings 82:2, 166-170
CrossRef320
Nailya R. Bulatova, Al Motassem F. Yousef, Salah M. AbuRuz. (2007) Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus. Thrombosis Research 121:1, 43-50
CrossRef321
Ingo Ahrens, Meike Schwarz, Karlheinz Peter, Christoph Bode. (2007) Therapeutic Inhibitors of Platelet Aggregation – from Aspirin to Integrin Blockersf. Transfusion Medicine and Hemotherapy 34:1, 44-54
CrossRef322
Takaaki Sakai, Keijiro Saku. (2007) A Health-economic Evaluation of Aspirin: Primary Prevention and Cardiovascular Disease. Internal Medicine 46:8, 431-433
CrossRef323
Alexander R. Opotowsky, J. Michael McWilliams, Christopher P. Cannon. (2007) Gender Differences in Aspirin use Among Adults With Coronary Heart Disease in the United States. Journal of General Internal Medicine 22:1, 55-61
CrossRef324
Eric R. Bates, Joseph D. Babb, Donald E. Casey, Christopher U. Cates, Gary R. Duckwiler, Ted E. Feldman, William A. Gray, Kenneth Ouriel, Eric D. Peterson, Kenneth Rosenfield, John H. Rundback, Robert D. Safian, Michael A. Sloan, Christopher J. White, Robert A. Harrington, Jonathan Abrams, Jeffrey L. Anderson, Eric R. Bates, Mark J. Eisenberg, Cindy L. Grines, Mark A. Hlatky, Robert C. Lichtenberg, Jonathan R. Lindner, Gerald M. Pohost, Richard S. Schofield, Samuel J. Shubrooks, James H. Stein, Cynthia M. Tracy, Robert A. Vogel, Deborah J. Wesley. (2007) ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting. Journal of the American College of Cardiology 49:1, 126-170
CrossRef325
Alfred A. Bartolucci. (2007) Meta-Analysis: Some Clinical and Statistical Contributions in Several Medical Disciplines. Yonsei Medical Journal 48:2, 157
CrossRef326
Angel Lanas, James Scheiman. (2007) Low-dose aspirin and upper gastrointestinal damage:epidemiology, prevention and treatment. Current Medical Research and Opinion 23:1, 163-173
CrossRef327
G.L. Moneta. (2007) A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. Yearbook of Vascular Surgery 2007, 94-96
CrossRef328
Hideo WADA. (2007) Japanese Journal of Thrombosis and Hemostasis 18:2, 140-146
CrossRef329
Jose-Antonio Egido, María Alonso de Leciñana. (2007) Peculiarities of Stroke Risk in Women. Cerebrovascular Diseases 24:1, 76-83
CrossRef330
Jaime Gállego, Eduardo Martínez Vila, Roberto Muñoz. (2007) Patients at High Risk for Ischemic Stroke: Identification and Actions. Cerebrovascular Diseases 24:1, 49-63
CrossRef331
Kiichiro Tsutani, Ataru Igarashi, Keita Fujikawa, Thomas Evers, Maria Kubin, Mark Lamotte, Lieven Annemans. (2007) A Health Economic Evaluation of Aspirin in the Primary Prevention of Cardiovascular Disease in Japan. Internal Medicine 46:4, 157-162
CrossRef332
Richard C. Becker. 2007. Hemostatic Aspects of Cardiovascular Medicine. , 339-369.
CrossRef333
Brendan M. Everett, Tobias Kurth, Julie E. Buring, Paul M. Ridker. (2006) The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women. Journal of the American College of Cardiology 48:11, 2235-2242
CrossRef334
Rosaly Correa-de-Araujo. (2006) Serious Gaps: How the Lack of Sex/Gender-Based Research Impairs Health. Journal of Women's Health 15:10, 1116-1122
CrossRef335
Stacie E. Geller, Marci Goldstein Adams, Molly Carnes. (2006) Adherence to Federal Guidelines for Reporting of Sex and Race/Ethnicity in Clinical Trials. Journal of Women's Health 15:10, 1123-1131
CrossRef336
J. C. Becker, W. Domschke, T. Pohle. (2006) Medikamentöse Prävention gastrointestinaler Tumoren. Der Internist 47:12, 1229-1238
CrossRef337
Jaume Figueras. (2006) Mayor mortalidad en la angioplastia primaria en la mujer. ¿Sigue el enigma del sexo?. Revista Española de Cardiología 59:11, 1096-1098
CrossRef338
John A. Colwell. (2006) An appraisal of aspirin therapy in diabetes. Current Diabetes Reports 6:6, 409-410
CrossRef339
Neal M Davies, Jonathon K Reynolds, Megan R Undeberg, Brian J Gates, Yusuke Ohgami, Karina R Vega-Villa. (2006) Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal. Expert Review of Neurotherapeutics 6:11, 1643-1655
CrossRef340
D Charytan, R E Kuntz. (2006) The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney International
CrossRef341
Vera Bittner. 2006. Women and Coronary Heart Disease. , 689-720.
CrossRef342
PAUL A. GURBEL, UDAYA S. TANTRY. (2006) Aspirin and Clopidogrel Resistance: Consideration and Management. Journal of Interventional Cardiology 19:5, 439-448
CrossRef343
&NA;. (2006) Aspirin for Primary Prevention of Cardiovascular Disease (Revisited). Obstetrics & Gynecology 108:4, 1023
CrossRef344
Michael S. Lee, Scott D. Smith, Anat Galor, Gary S. Hoffman. (2006) Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis & Rheumatism 54:10, 3306-3309
CrossRef345
P. Ambrosi, P. Villani, G. Bouvenot. (2006) Antiplatelet therapy for primary prevention in diabetes. Diabetes & Metabolism 32, 2S52-2S56
CrossRef346
Virginia M. Miller, Muthuvel Jayachandran, John A. Heit, Whyte G. Owen. (2006) Estrogen therapy and thrombotic risk. Pharmacology & Therapeutics 111:3, 792-807
CrossRef347
Florian B. Mayr, Bernd Jilma. (2006) Current developments in anti-platelet therapy. Wiener Medizinische Wochenschrift 156:17-18, 472-480
CrossRef348
L. ANNEMANS, M. LAMOTTE, M. KUBIN, T. EVERS, F. W. A. VERHEUGT. (2006) Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. International Journal of Clinical Practice 60:9, 1129-1137
CrossRef349
L. LAINE. (2006) Review article: gastrointestinal bleeding with low-dose aspirin – what's the risk?. Alimentary Pharmacology and Therapeutics 24:6, 897-908
CrossRef350
Nan Chiang, Charles N. Serhan. (2006) New mechanism for an old drug Aspirin triggers anti-inflammatory lipid mediators with gender implications. Comprehensive Therapy 32:3, 150-157
CrossRef351
Psaty, Bruce M., Potter, John D., . (2006) Risks and Benefits of Celecoxib to Prevent Recurrent Adenomas. New England Journal of Medicine 355:9, 950-952
Full Text352
Pierre Théroux, Benoît Labarthe. (2006) Coping with new challenges in acute coronary syndromes. Canadian Journal of Cardiology 22, 13C-20C
CrossRef353
L Romayne Kurukulasuriya, Gurushankar Govindarajan, James Sowers. (2006) Stroke prevention in diabetes and obesity. Expert Review of Cardiovascular Therapy 4:4, 487-502
CrossRef354
Moira K Kapral. (2006) Stroke management in women. Women's Health 2:4, 597-603
CrossRef355
Matt Fisher, Volker Knappertz. (2006) The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. Current Medical Research and Opinion 22:7, 1239-1248
CrossRef356
Abha Gulati, Rose Sullivan, Julie E. Buring, David A. Sullivan, Reza Dana, Debra A. Schaumberg. (2006) Validation and Repeatability of a Short Questionnaire for Dry Eye Syndrome. American Journal of Ophthalmology 142:1, 125-131.e2
CrossRef357
. (2006) NHG-Standaard Cardiovasculair risicomanagement (2). Huisarts en Wetenschap 49:7, 530-531
CrossRef358
Tobias Kurth, Hans-Christoph Diener. (2006) Current views of the risk of stroke for migraine with and migraine without aura. Current Pain and Headache Reports 10:3, 214-220
CrossRef359
James M. Gebel. (2006) Reply. Journal of the American College of Cardiology 47:12, 2569-2570
CrossRef360
Fenella J. Kirkham, Norma B. Lerner, Michael Noetzel, Michael R. DeBaun, Avijit K. Datta, David C. Rees, Robert J. Adams. (2006) Trials in Sickle Cell Disease. Pediatric Neurology 34:6, 450-458
CrossRef361
Kai I. Cheang. (2006) Cardiovascular Risk Reduction. The Consultant Pharmacist 21:6, 493-499
CrossRef362
Heather L. Horton. (2006) Secondary Stroke Prevention and Antiplatelet Therapy. Journal of the American College of Cardiology 47:12, 2568
CrossRef363
S. Moncada. (2006) Adventures in vascular biology: a tale of two mediators. Philosophical Transactions of the Royal Society B: Biological Sciences 361:1469, 735-759
CrossRef364
Udaya S Tantry, Amena Etherington, Kevin P Bliden, Paul A Gurbel. (2006) Antiplatelet therapy: current strategies and future trends. Future Cardiology 2:3, 343-366
CrossRef365
N. M. Schmitt, W. Kirch. (2006) Besonderheiten der Pharmakotherapie bei Frauen im Alter. Der Gynäkologe 39:5, 367-372
CrossRef366
Vera Regitz-Zagrosek. (2006) Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nature Reviews Drug Discovery 5:5, 425-239
CrossRef367
Silvina B. Tonarelli, Robert G. Hart. (2006) What's New in Stroke? The Top 10 for 2004/05. Journal of the American Geriatrics Society 54:4, 674-679
CrossRef368
Nanette K Wenger. (2006) Coronary heart disease in women: highlights of the past 2 years—stepping stones, milestones and obstructing boulders. Nature Clinical Practice Cardiovascular Medicine 3:4, 194-202
CrossRef369
D I Chasman, P Kozlowski, R Y Zee, D J Kwiatkowski, P M Ridker. (2006) Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes and Immunity 7:3, 211-219
CrossRef370
Thomas M. MacDonald, Li Wei. (2006) Is there an Interaction between the Cardiovascular Protective Effects of Low-Dose Aspirin and Ibuprofen?. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 98:3, 275-280
CrossRef371
Fernando Alfonso, Javier Bermejo, Javier Segovia. (2006) Enfermedades cardiovasculares en la mujer: ¿por qué ahora?. Revista Española de Cardiología 59:3, 259-263
CrossRef372
Allison H. Christian, Thomas Mills, Susan Lee Simpson, Lori Mosca. (2006) Quality of Cardiovascular Disease Preventive Care and Physician/Practice Characteristics. Journal of General Internal Medicine 21:3, 231-237
CrossRef373
J.M. Mostaza, C. Lahoz. (2006) Utilización combinada de fármacos para la prevención cardiovascular: más allá de una polipastilla. Clínica e Investigación en Arteriosclerosis 18:1, 35-39
CrossRef374
Christian Weimar, Hans-Christoph Diener. (2006) What’s new in stroke prevention and treatment. Expert Review of Neurotherapeutics 6:2, 185-193
CrossRef375
W. Dallas Hall, Laurence O. Watkins, Jackson T. Wright, Nanette K. Wenger, Shiriki K. Kumanyika, James R. Gavin, Keith C. Ferdinand, Karol Watson, Luther T. Clark, John M. Flack, James W. Reed, Ella W. Horton, Elijah Saunders. (2006) The Metabolic Syndrome: Recognition and Management. Disease Management 9:1, 16-33
CrossRef376
Curry L. Koening, Carol A. Langford. (2006) Novel Therapeutic Strategies for Large Vessel Vasculitis. Rheumatic Disease Clinics of North America 32:1, 173-186
CrossRef377
James Butcher, William Summerskill. (2006) The research legacy of 2005. The Lancet 367:9511, 636
CrossRef378
Glen E. Cooke. (2006) Pharmacogenetics of multigenic disease: Heart disease as an example. Vascular Pharmacology 44:2, 66-74
CrossRef379
Randolph W. Evans, Werner J. Becker. (2006) Migraine and Oral Contraceptives. Headache: The Journal of Head and Face Pain 46:2, 328-331
CrossRef380
H.-R. Koelz, M. Arn. (2006) Neue Epidemiologie der akuten gastrointestinalen Blutung. Der Chirurg 77:2, 103-110
CrossRef381
Christopher Sibley, Roger S. Blumenthal, C. Noel Bairey Merz, Lori Mosca. (2006) Commentary : Limitations of Current Cardiovascular Disease Risk Assessment Strategies in Women. Journal of Women's Health 15:1, 54-56
CrossRef382
Michael Hoffmeister, Jenny Chang-Claude, Hermann Brenner. (2006) Do Older Adults Using NSAIDs Have a Reduced Risk of Colorectal Cancer?. Drugs & Aging 23:6, 513-523
CrossRef383
Eli I. Lev, Rajnikant T. Patel, Kelly J. Maresh, Sasidhar Guthikonda, Juan Granada, Timothy DeLao, Paul F. Bray, Neal S. Kleiman. (2006) Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology 47:1, 27-33
CrossRef384
Jacqueline Müller-Nordhorn, Christian H. Nolte, Karin Rossnagel, Gerhard J. Jungehülsing, Andreas Reich, Stephanie Roll, Arno Villringer, Stefan N. Willich. (2006) Medical Management in Patients following Stroke and Transitory Ischemic Attack: A Comparison between Men and Women. Cerebrovascular Diseases 21:5-6, 329-335
CrossRef385
Bruce Ovbiagele, Jeffrey L. Saver. (2006) Cerebral White Matter Hyperintensities on MRI: Current Concepts and Therapeutic Implications. Cerebrovascular Diseases 22:2-3, 83-90
CrossRef386
Cheol Whan Lee. (2006) Aspirin for the Prevention of Cardiovascular Events. Journal of the Korean Medical Association 49:2, 181
CrossRef387
Mark Lamotte, Lieven Annemans, Thomas Evers, Maria Kubin. (2006) A Multi-Country Economic Evaluation of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease. PharmacoEconomics 24:2, 155-169
CrossRef388
Nekane Murga Eizagaechevarria, Milagros Pedreira Pérez, Pilar Mazón Ramos, Ángeles Alonso García. (2006) Temas de actualidad en cardiología clínica y extrahospitalaria. Un nuevo proyecto: enfermedad cardiovascular en la mujer. Revista Española de Cardiología 59, 99-104
CrossRef389
Alfredo Bardají, Joaquín Alonso, Xavier García-Moll, Héctor Bueno. (2006) Actualización en cardiopatía isquémica 2005. Revista Española de Cardiología 59, 3-19
CrossRef390
Hisahiro Yoshida, Satoko Takada. (2006) Is it Possible to Screen Patients for Aspirin Resistance Using 11-dehydro-Thromboxane B2 Spot Urine Levels?. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 32:12, 1242-1247
CrossRef391
Marc Maillard, Michel Burnier. (2006) Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opinion on Drug Safety 5:1, 83-94
CrossRef392
B.J. Gersh. (2006) A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. Yearbook of Cardiology 2006, 270-272
CrossRef393
Charles H Hennekens, Danielle Hollar, Colin Baigent. (2006) Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis. Nature Clinical Practice Cardiovascular Medicine 3:1, 4-5
CrossRef394
Costantina Manes, Luciano Giacci, Adolfo Sciartilli, Alberto D'Alleva, Raffaele De Caterina. (2006) Aspirin overprescription in primary cardiovascular prevention. Thrombosis Research 118:4, 471-477
CrossRef395
Patrono, Carlo, García Rodríguez, Luis A., Landolfi, Raffaele, Baigent, Colin, . (2005) Low-Dose Aspirin for the Prevention of Atherothrombosis. New England Journal of Medicine 353:22, 2373-2383
Full Text396
Cheryl D Bushnell. (2005) Oestrogen and stroke in women: assessment of risk. The Lancet Neurology 4:11, 743-751
CrossRef397
Michael Galindo, Lorinda Chung, Seth D Crockett, Eliza F Chakravarty. (2005) Coronary artery disease in patients with systemic lupus erythematosus. Nature Clinical Practice Rheumatology 1:1, 55-59
CrossRef398
I U Ali, B T Luke, M Dean, P Greenwald. (2005) Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. British Journal of Cancer 93:8, 953-959
CrossRef399
Udaya S Tantry, Kevin P Bliden, Paul A Gurbel. (2005) Resistance to antiplatelet drugs: current status and future research. Expert Opinion on Pharmacotherapy 6:12, 2027-2045
CrossRef400
H. Gohlke, G. Schuler. (2005) Empfehlungen zur Prävention und evidenzbasierte Medizin. Zeitschrift für Kardiologie 94:S3, iii1-iii5
CrossRef401
Freek WA Verheugt, Sidney C Smith. (2005) The lady aspirin for cardiovascular disease. The Lancet 366:9492, 1148-1150
CrossRef402
Charles N. Serhan. (2005) Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins, Leukotrienes and Essential Fatty Acids 73:3-4, 141-162
CrossRef403
(2005) Primärprävention kardiovaskulärer Erkrankungen bei Frauen. Der Internist 46:9, 1043-1046
CrossRef404
Claire S Duvernoy. (2005) Coronary heart disease in women: what do we know now?. Future Cardiology 1:5, 617-628
CrossRef405
Aziz Maksoud, Robert C. Candipan, David B. Wilson, James L. Vacek. (2005) Aspirin and Clopidogrel: Efficacy, Treatment, and Resistance in Coronary Artery Disease. International Journal of Angiology 14:3, 109-114
CrossRef406
Maria I Aguilar, Robert Hart, Robert Hart. 2005. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. .
CrossRef407
Wendy M Miller, Katherine E Nori Janosz, Jose Yanez, Peter A McCullough. (2005) Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. Expert Review of Cardiovascular Therapy 3:4, 743-759
CrossRef408
Shari S Bassuk, Paul M Ridker, JoAnn E Manson, Julie E Buring. (2005) Aspirin and cardiovascular disease prevention in women: new findings from the Women’s Health Study. Women's Health 1:1, 9-10
CrossRef409
(2005) Aspirin in the Prevention of Cardiovascular Disease in Women. New England Journal of Medicine 352:26, 2751-2752
Full Text410
Philip R Liebson. (2005) Womens? Health Study (Aspirin) and TNT. Preventive Cardiology 8:3, 181-185
CrossRef411
Michael G. Miller, B. Daniel Lucas, Vasilios Papademetriou, Abdul-karim Elhabyan. (2005) Aspirin Under Fire: Aspirin Use in the Primary Prevention of Coronary Heart Disease. Pharmacotherapy 25:6, 847-861
CrossRef412
Bruce B. Lerman, Richard B. Devereux, Peter M. Okin. (2005) An Introduction. Journal of the American College of Cardiology 45:11, B2-B3
CrossRef413
H. R. Vries. (2005) ASA ter voorkoming van een hartinfarct werkt niet bij vrouwen. Medisch-Farmaceutische Mededelingen 43:6, 164-165
CrossRef414
(2005) Hot Papers In The Literature. Journal of Women's Health 14:5, 452-457
CrossRef415
(2005) Does aspirin protect women against cardiovascular disease?. Nature Clinical Practice Cardiovascular Medicine 2:5, 228-229
CrossRef416
Rosemarie A Reiter, Bernd Jilma. (2005) Platelets and new antiplatelet drugs. Therapy 2:3, 465-502
CrossRef417
Daniel Schneider, Judith Hsia. (2005) Coronary heart disease prevention in menopausal women. Expert Opinion on Pharmacotherapy 6:5, 695-705
CrossRef418
Levin, Richard I., . (2005) The Puzzle of Aspirin and Sex. New England Journal of Medicine 352:13, 1366-1368
Full Text419
Ditina Desai, Ahmed Hasan, Robert Wesley, Edwin Sunderland, Frank Pucino, Gyorgy Csako. (2005) Effects of dietary supplements on aspirin and other antiplatelet agents: An evidence-based approach. Thrombosis Research 117:1-2, 87-101
CrossRef420
Randall S. Stafford, Veronica Monti, Jun Ma. (2005) Underutilization of Aspirin Persists in US Ambulatory Care for the Secondary and Primary Prevention of Cardiovascular Disease. PLoS Medicine 2:12, e353
CrossRef421
G Bjelakovic, D Nikolova, RG Simonetti, C Gluud, Goran Bjelakovic. 2004. Antioxidant supplements for preventing gastrointestinal cancers. .
CrossRef
- Letters
